PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 10463616-1 1999 We have previously demonstrated that halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 136-162 11099465-1 2000 We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 146-172 11099465-1 2000 We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 174-179 11099465-6 2000 The most conclusive anti-angiogenic activity of halofuginone was demonstrated in vivo (mouse corneal micropocket assay) by showing a marked inhibition of basic fibroblast growth factor (bFGF) -induced neovascularization in response to systemic administration of halofuginone, either i.p. halofuginone 48-60 fibroblast growth factor 2 Mus musculus 154-184 11099465-6 2000 The most conclusive anti-angiogenic activity of halofuginone was demonstrated in vivo (mouse corneal micropocket assay) by showing a marked inhibition of basic fibroblast growth factor (bFGF) -induced neovascularization in response to systemic administration of halofuginone, either i.p. halofuginone 48-60 fibroblast growth factor 2 Mus musculus 186-190 11099465-6 2000 The most conclusive anti-angiogenic activity of halofuginone was demonstrated in vivo (mouse corneal micropocket assay) by showing a marked inhibition of basic fibroblast growth factor (bFGF) -induced neovascularization in response to systemic administration of halofuginone, either i.p. halofuginone 262-274 fibroblast growth factor 2 Mus musculus 186-190 10772506-9 2000 The epithelium was significantly thicker in the animals that received halofunginone than in the controls or animals receiving EGF. halofuginone 70-83 epidermal growth factor Sus scrofa 126-129 34954499-4 2022 Activation of GCN2 by halofuginone treatment or leucine deprivation decreased NRF2 expression in hepatocytes by increasing GSK-3beta activity. halofuginone 22-34 eukaryotic translation initiation factor 2 alpha kinase 4 Mus musculus 14-18 10473075-0 1999 Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. halofuginone 88-100 matrix metallopeptidase 2 Mus musculus 14-40 10473075-5 1999 We now report that expression of the MMP-2 gene by murine (MBT2-t50) and human (5637) bladder carcinoma cells is highly susceptible to inhibition by halofuginone. halofuginone 149-161 matrix metallopeptidase 2 Mus musculus 37-42 10473075-7 1999 This inhibition is due to an effect of halofuginone on the activity of the MMP-2 promoter, as indicated by a pronounced suppression of chloramphenicol acetyltransferase activity driven by the MMP-2 promoter in transfected MBT2 cells. halofuginone 39-51 matrix metallopeptidase 2 Mus musculus 75-80 10473075-7 1999 This inhibition is due to an effect of halofuginone on the activity of the MMP-2 promoter, as indicated by a pronounced suppression of chloramphenicol acetyltransferase activity driven by the MMP-2 promoter in transfected MBT2 cells. halofuginone 39-51 matrix metallopeptidase 2 Mus musculus 192-197 10473075-9 1999 Halofuginone-treated cells failed to invade through reconstituted basement-membrane (Matrigel) coated filters, in accordance with the inhibition of MMP-2 gene expression. halofuginone 0-12 matrix metallopeptidase 2 Mus musculus 148-153 10473075-13 1999 These results indicate that the potent antimetastatic activity of halofuginone is due primarily to a transcriptional suppression of the MMP-2 gene, which results in a decreased enzymatic activity, matrix degradation, and tumor cell extravasation. halofuginone 66-78 matrix metallopeptidase 2 Mus musculus 136-141 33799176-3 2021 Three aaRS inhibitors are already in clinical practice; antibacterial mupirocin inhibits the synthetic site of isoleucyl-tRNA synthetase, antifungal tavaborole inhibits the editing site of leucyl-tRNA synthetase, and antiprotozoal halofuginone inhibits proline-tRNA synthetase. halofuginone 231-243 alanyl-tRNA synthetase 1 Homo sapiens 6-10 33799176-3 2021 Three aaRS inhibitors are already in clinical practice; antibacterial mupirocin inhibits the synthetic site of isoleucyl-tRNA synthetase, antifungal tavaborole inhibits the editing site of leucyl-tRNA synthetase, and antiprotozoal halofuginone inhibits proline-tRNA synthetase. halofuginone 231-243 isoleucyl-tRNA synthetase 1 Homo sapiens 111-136 34954499-4 2022 Activation of GCN2 by halofuginone treatment or leucine deprivation decreased NRF2 expression in hepatocytes by increasing GSK-3beta activity. halofuginone 22-34 nuclear factor, erythroid derived 2, like 2 Mus musculus 78-82 34954499-4 2022 Activation of GCN2 by halofuginone treatment or leucine deprivation decreased NRF2 expression in hepatocytes by increasing GSK-3beta activity. halofuginone 22-34 glycogen synthase kinase 3 alpha Mus musculus 123-132 34901018-0 2021 Halofuginone Sensitizes Lung Cancer Organoids to Cisplatin via Suppressing PI3K/AKT and MAPK Signaling Pathways. halofuginone 0-12 AKT serine/threonine kinase 1 Homo sapiens 80-83 34901018-7 2021 Gene expression profiling and KEGG analysis indicated that PI3K/AKT and MAPK signaling pathways were top-ranked pathways affected by halofuginone. halofuginone 133-145 AKT serine/threonine kinase 1 Homo sapiens 64-67 34321315-3 2021 We found that halofuginone administration decreased the number of pancreatic intraepithelial neoplasias in pancreas-specific Kras and p53 mutant (KPC) mice. halofuginone 14-26 Kirsten rat sarcoma viral oncogene homolog Mus musculus 125-129 34628069-0 2022 Halofuginone enhances the anti-tumor effect of ALA-PDT by suppressing NRF2 signaling in cSCC. halofuginone 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 70-74 34321315-3 2021 We found that halofuginone administration decreased the number of pancreatic intraepithelial neoplasias in pancreas-specific Kras and p53 mutant (KPC) mice. halofuginone 14-26 transformation related protein 53, pseudogene Mus musculus 134-137 35618180-0 2022 Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity. halofuginone 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 45-49 34321315-4 2021 In Nrf2-activated pancreatic cancer cell lines established from KPC mice, halofuginone rapidly depleted Nrf2 in Nrf2-activated cancer cells. halofuginone 74-86 nuclear factor, erythroid derived 2, like 2 Mus musculus 104-108 34321315-4 2021 In Nrf2-activated pancreatic cancer cell lines established from KPC mice, halofuginone rapidly depleted Nrf2 in Nrf2-activated cancer cells. halofuginone 74-86 nuclear factor, erythroid derived 2, like 2 Mus musculus 112-116 34321315-6 2021 In our mechanistic study, we found that halofuginone downregulated ALDH3A1 in mouse pancreatic cancer cells. halofuginone 40-52 aldehyde dehydrogenase family 3, subfamily A1 Mus musculus 67-74 34321315-8 2021 The current study demonstrated the therapeutic benefits of halofuginone in Nrf2-activated pancreatic cancers. halofuginone 59-71 nuclear factor, erythroid derived 2, like 2 Mus musculus 75-79 34162861-4 2021 We identify homoharringtonine and halofuginone as the most attractive agents, reducing endogenous TMPRSS2 expression at sub-micromolar concentrations. halofuginone 34-46 transmembrane serine protease 2 Homo sapiens 98-105 34162861-6 2021 We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). halofuginone 28-40 transmembrane serine protease 2 Homo sapiens 51-58 34162861-6 2021 We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). halofuginone 28-40 DDB1 and CUL4 associated factor 1 Homo sapiens 155-189 34162861-6 2021 We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). halofuginone 28-40 DDB1 and CUL4 associated factor 1 Homo sapiens 191-196 34401503-1 2021 Objectives: To evaluate antifibrotic effects of corticosteroids and halofuginone, a small molecule inhibitor of Smad3, in an ovine model of vocal fold (VF) injury. halofuginone 68-80 mothers against decapentaplegic homolog 3 Ovis aries 112-117 34401503-7 2021 Elastin was preserved postinjury by halofuginone treatment in contrast with all steroid treated animals where significant loss of elastin was noted (P <.05). halofuginone 36-48 elastin Ovis aries 0-7 34401503-8 2021 Smad3 staining was up-regulated at all injury sites compared to normal left VFs however halofuginone and dexamethasone treatment reduced Smad3 activity significantly whereas triamcinolone treatment did not (P <.05). halofuginone 88-100 mothers against decapentaplegic homolog 3 Ovis aries 137-142 34401503-10 2021 Conclusions: VF injury in an ovine model results in a wound response able to be modified by Smad3 inhibitor, halofuginone, with benefit to vibratory function. halofuginone 109-121 mothers against decapentaplegic homolog 3 Ovis aries 92-97 34401503-11 2021 Halofuginone treated sheep demonstrated reduced collagenization of lamina propria with greater elastin density after injury, than sheep treated with either steroid medication. halofuginone 0-12 elastin Ovis aries 95-102 35636724-5 2022 We discuss mechanistic insights into halofuginone"s primary mode of action, which involves inhibition of the prolyl-tRNA synthetase enzyme, which is crucial in protein synthesis. halofuginone 37-49 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 109-131 34209117-9 2021 A significant reduction in collagen content and degenerative areas, and an increase in utrophin levels were observed in diaphragms of mice treated with racemic halofuginone. halofuginone 160-172 utrophin Mus musculus 87-95 35466425-0 2022 Cellular responses to halofuginone reveal a vulnerability of the GCN2 branch of the integrated stress response. halofuginone 22-34 eukaryotic translation initiation factor 2 alpha kinase 4 Homo sapiens 65-69 35466425-1 2022 Halofuginone (HF) is a phase 2 clinical compound that inhibits the glutamyl-prolyl-tRNA synthetase (EPRS) thereby inducing the integrated stress response (ISR). halofuginone 0-12 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 67-98 35466425-1 2022 Halofuginone (HF) is a phase 2 clinical compound that inhibits the glutamyl-prolyl-tRNA synthetase (EPRS) thereby inducing the integrated stress response (ISR). halofuginone 0-12 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 100-104 35466425-7 2022 This work reveals that the consequences of EPRS inhibition are more complex than anticipated and provides novel insights into ISR signaling, as well as a molecular framework to guide the targeted development of halofuginone as a therapeutic. halofuginone 211-223 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 43-47 35618180-5 2022 We previously identified Halofuginone (HF) as a promising Nrf2 inhibitor. halofuginone 25-37 NFE2 like bZIP transcription factor 2 Homo sapiens 58-62 33729485-6 2021 Halofuginone (HF) has been recently identified as a potent Nrf2 synthetic inhibitor, and its treatment of Cab-R cells not only suppressed the Nrf2 signaling by decreasing both nuclear and cytosolic Nrf2 protein levels, but also significantly augmented the cabazitaxel sensitivity. halofuginone 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 59-63 33791697-6 2021 We find that pp1a and pp1ab polyproteins of SARS-CoV-2, as well as several HS proteoglycans, are proline-rich, which may make them particularly vulnerable to halofuginone"s translational suppression. halofuginone 158-170 protein phosphatase 1 catalytic subunit alpha Homo sapiens 13-17 34405694-6 2022 Combined treatment of VSV and halofuginone also modulates the immunosuppressive TME via deletion of TAM, MDSCs, and regulatory T cells (Tregs). halofuginone 30-42 Myeloproliferative syndrome, transient (transient abnormal myelopoiesis) Homo sapiens 100-103 33791697-0 2021 The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection. halofuginone 37-49 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 4-26 33791697-1 2021 We identify the prolyl-tRNA synthetase (PRS) inhibitor halofuginone 1 , a compound in clinical trials for anti-fibrotic and anti-inflammatory applications 2 , as a potent inhibitor of SARS-CoV-2 infection and replication. halofuginone 55-67 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 16-38 33791697-1 2021 We identify the prolyl-tRNA synthetase (PRS) inhibitor halofuginone 1 , a compound in clinical trials for anti-fibrotic and anti-inflammatory applications 2 , as a potent inhibitor of SARS-CoV-2 infection and replication. halofuginone 55-67 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 40-43 33791697-3 2021 We find that halofuginone reduces HS biosynthesis, thereby reducing spike protein binding, SARS-CoV-2 pseudotyped virus, and authentic SARS-CoV-2 infection. halofuginone 13-25 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 68-73 33729485-6 2021 Halofuginone (HF) has been recently identified as a potent Nrf2 synthetic inhibitor, and its treatment of Cab-R cells not only suppressed the Nrf2 signaling by decreasing both nuclear and cytosolic Nrf2 protein levels, but also significantly augmented the cabazitaxel sensitivity. halofuginone 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 142-146 33729485-6 2021 Halofuginone (HF) has been recently identified as a potent Nrf2 synthetic inhibitor, and its treatment of Cab-R cells not only suppressed the Nrf2 signaling by decreasing both nuclear and cytosolic Nrf2 protein levels, but also significantly augmented the cabazitaxel sensitivity. halofuginone 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 142-146 32707492-5 2020 Through this study, we demonstrate that Halofuginone ameliorates LPS-induced attachment of THP-1 cells to HUVECs by inhibiting the expressions of adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1) and E-selectin. halofuginone 40-52 vascular cell adhesion molecule 1 Homo sapiens 176-209 33433355-0 2021 Halofuginone regulates keloid fibroblast fibrotic response to TGF-beta induction. halofuginone 0-12 transforming growth factor alpha Homo sapiens 62-70 33433355-3 2021 Here we analyze the antifibrotic mechanisms of Halofuginone (HF), a drug reportedly able to inhibit the TGF-beta1-Smad3 pathway and to attenuate collagen synthesis, in an in-vitro keloid model using patient-derived Keloid Fibroblasts (KFs) isolated from fibrotic tissue collected during the "Scar Wars" clinical study (NCT NCT03312166). halofuginone 47-59 transforming growth factor beta 1 Homo sapiens 104-113 33433355-3 2021 Here we analyze the antifibrotic mechanisms of Halofuginone (HF), a drug reportedly able to inhibit the TGF-beta1-Smad3 pathway and to attenuate collagen synthesis, in an in-vitro keloid model using patient-derived Keloid Fibroblasts (KFs) isolated from fibrotic tissue collected during the "Scar Wars" clinical study (NCT NCT03312166). halofuginone 47-59 SMAD family member 3 Homo sapiens 114-119 33154782-0 2020 Halofuginone inhibits tumorigenic progression of 5-FU-resistant human colorectal cancer HCT-15/FU cells by targeting miR-132-3p in vitro. halofuginone 0-12 microRNA 1323 Homo sapiens 117-127 32707492-9 2020 Mechanistically, we find the protective effects of Halofuginone depend on the expression of Kruppel-like factor 2 (KLF2), which is mediated by extracellular regulated protein kinases 5 (ERK5). halofuginone 51-63 Kruppel like factor 2 Homo sapiens 92-113 32707492-9 2020 Mechanistically, we find the protective effects of Halofuginone depend on the expression of Kruppel-like factor 2 (KLF2), which is mediated by extracellular regulated protein kinases 5 (ERK5). halofuginone 51-63 Kruppel like factor 2 Homo sapiens 115-119 32707492-9 2020 Mechanistically, we find the protective effects of Halofuginone depend on the expression of Kruppel-like factor 2 (KLF2), which is mediated by extracellular regulated protein kinases 5 (ERK5). halofuginone 51-63 mitogen-activated protein kinase 7 Homo sapiens 143-184 32707492-9 2020 Mechanistically, we find the protective effects of Halofuginone depend on the expression of Kruppel-like factor 2 (KLF2), which is mediated by extracellular regulated protein kinases 5 (ERK5). halofuginone 51-63 mitogen-activated protein kinase 7 Homo sapiens 186-190 32707492-5 2020 Through this study, we demonstrate that Halofuginone ameliorates LPS-induced attachment of THP-1 cells to HUVECs by inhibiting the expressions of adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1) and E-selectin. halofuginone 40-52 vascular cell adhesion molecule 1 Homo sapiens 211-217 32707492-5 2020 Through this study, we demonstrate that Halofuginone ameliorates LPS-induced attachment of THP-1 cells to HUVECs by inhibiting the expressions of adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1) and E-selectin. halofuginone 40-52 selectin E Homo sapiens 223-233 32707492-6 2020 Halofuginone also suppresses the production of pro-inflammatory cytokines, including tumor necrosis factor alpha. halofuginone 0-12 tumor necrosis factor Homo sapiens 85-112 32707492-8 2020 Furthermore, Halofuginone reduces the overproduction of reactive oxygen species (ROS) by regulating the expression of NADPH oxidase 2 (NOX-2). halofuginone 13-25 cytochrome b-245 beta chain Homo sapiens 118-133 32707492-8 2020 Furthermore, Halofuginone reduces the overproduction of reactive oxygen species (ROS) by regulating the expression of NADPH oxidase 2 (NOX-2). halofuginone 13-25 cytochrome b-245 beta chain Homo sapiens 135-140 32679143-0 2020 Significance of halofuginone in esophageal squamous carcinoma cell apoptosis through HIF-1alpha-FOXO3a pathway. halofuginone 16-28 hypoxia inducible factor 1 subunit alpha Homo sapiens 85-95 32679143-0 2020 Significance of halofuginone in esophageal squamous carcinoma cell apoptosis through HIF-1alpha-FOXO3a pathway. halofuginone 16-28 forkhead box O3 Homo sapiens 96-102 32818215-4 2020 Among these, homoharringtonine and halofuginone appear the most potent agents, reducing endogenous TMPRSS2 expression at sub-micromolar concentrations. halofuginone 35-47 transmembrane serine protease 2 Homo sapiens 99-106 32437065-3 2020 In this study, the anti-proliferative and apoptotic effects of Halofuginone were investigated through its ability to deregulate EGFR downstream signalling cascade proteins in the pathologically aggressive malignant mesothelioma and non-small cell lung cancer cells. halofuginone 63-75 epidermal growth factor receptor Homo sapiens 128-132 32611237-7 2020 Inhibition of EPRS using a prolyl-tRNA synthetase (PRS)-specific inhibitor, halofuginone (Halo), significantly decreases translation efficiency of proline-rich collagens in cardiac fibroblasts as well as TGF-beta-activated myofibroblasts. halofuginone 76-88 glutamyl-prolyl-tRNA synthetase Mus musculus 14-18 32611237-7 2020 Inhibition of EPRS using a prolyl-tRNA synthetase (PRS)-specific inhibitor, halofuginone (Halo), significantly decreases translation efficiency of proline-rich collagens in cardiac fibroblasts as well as TGF-beta-activated myofibroblasts. halofuginone 76-88 transforming growth factor alpha Mus musculus 204-212 32611237-7 2020 Inhibition of EPRS using a prolyl-tRNA synthetase (PRS)-specific inhibitor, halofuginone (Halo), significantly decreases translation efficiency of proline-rich collagens in cardiac fibroblasts as well as TGF-beta-activated myofibroblasts. halofuginone 90-94 glutamyl-prolyl-tRNA synthetase Mus musculus 14-18 32611237-7 2020 Inhibition of EPRS using a prolyl-tRNA synthetase (PRS)-specific inhibitor, halofuginone (Halo), significantly decreases translation efficiency of proline-rich collagens in cardiac fibroblasts as well as TGF-beta-activated myofibroblasts. halofuginone 90-94 transforming growth factor alpha Mus musculus 204-212 32818215-6 2020 We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). halofuginone 28-40 transmembrane serine protease 2 Homo sapiens 51-58 32818215-6 2020 We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). halofuginone 28-40 DDB1 and CUL4 associated factor 1 Homo sapiens 155-189 32818215-6 2020 We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). halofuginone 28-40 DDB1 and CUL4 associated factor 1 Homo sapiens 191-196 30773881-1 2019 We have previously identified the cytoplasmic prolyl tRNA synthetase in Plasmodium falciparum as the functional target of the natural product febrifugine and its synthetic analogue halofuginone (HFG), one of the most potent antimalarials discovered to date. halofuginone 181-193 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 46-68 32451154-0 2020 Early pathological signs in young dysf-/- mice are improved by halofuginone. halofuginone 63-75 dysferlin Mus musculus 34-38 32451154-6 2020 Continuous treatment with halofuginone from 4 weeks to 5 months of age reduced muscle fibrosis in a phosphorylated-Smad3 inhibition-related manner. halofuginone 26-38 SMAD family member 3 Mus musculus 115-120 32253314-2 2020 Our laboratory has previously shown that halofuginone (HF) inhibits the prolyl-tRNA synthetase catalytic activity of glutamyl-prolyl-tRNA synthetase (EPRS), thereby activating the amino acid response (AAR). halofuginone 41-53 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 72-94 32253314-2 2020 Our laboratory has previously shown that halofuginone (HF) inhibits the prolyl-tRNA synthetase catalytic activity of glutamyl-prolyl-tRNA synthetase (EPRS), thereby activating the amino acid response (AAR). halofuginone 41-53 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 117-148 32253314-2 2020 Our laboratory has previously shown that halofuginone (HF) inhibits the prolyl-tRNA synthetase catalytic activity of glutamyl-prolyl-tRNA synthetase (EPRS), thereby activating the amino acid response (AAR). halofuginone 41-53 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 150-154 30628720-5 2019 Halofuginone caused a significant reduction in total collagen content, degenerative areas, as well as in utrophin and phosphorylated-Smad3 levels in the mdx diaphragms. halofuginone 0-12 utrophin Mus musculus 105-113 30628720-5 2019 Halofuginone caused a significant reduction in total collagen content, degenerative areas, as well as in utrophin and phosphorylated-Smad3 levels in the mdx diaphragms. halofuginone 0-12 SMAD family member 3 Mus musculus 133-138 30628720-8 2019 It is concluded that the hydroxy group plays a key role in halofuginone"s effects related to fibrosis in DMD, and points towards the transforming growth factor beta/Smad3 signaling pathway being involved in this inhibition. halofuginone 59-71 SMAD family member 3 Mus musculus 165-170 31261724-4 2019 Administration of halofuginone showed a significant neuroprotective effect by inhibiting HIF-1alpha expression in a murine retinal ischemia-reperfusion model histologically and functionally. halofuginone 18-30 hypoxia inducible factor 1, alpha subunit Mus musculus 89-99 31046663-12 2019 Sequence alignments of helminth-encoded lysyl, prolyl, leucyl and threonyl tRNA synthetases suggest that various known aaRS inhibitors like Cladosporin, Halofuginone, Benzoborale and Borrelidin may be of utility against helminths. halofuginone 153-165 alanyl-tRNA synthetase 1 Homo sapiens 119-123 33259259-6 2020 We demonstrated that the administration of halofuginone significantly reduced the expression levels of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) in vivo, and markedly suppressed immune cell infiltration into the infected sites. halofuginone 43-55 interleukin 1 alpha Mus musculus 131-139 33259259-6 2020 We demonstrated that the administration of halofuginone significantly reduced the expression levels of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) in vivo, and markedly suppressed immune cell infiltration into the infected sites. halofuginone 43-55 interleukin 6 Mus musculus 141-145 33259259-6 2020 We demonstrated that the administration of halofuginone significantly reduced the expression levels of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) in vivo, and markedly suppressed immune cell infiltration into the infected sites. halofuginone 43-55 tumor necrosis factor Mus musculus 151-160 32457283-0 2020 Involvement of eIF2alpha in halofuginone-driven inhibition of TGF-beta1-induced EMT. halofuginone 28-40 eukaryotic translation initiation factor 2A Sus scrofa 15-24 32457283-0 2020 Involvement of eIF2alpha in halofuginone-driven inhibition of TGF-beta1-induced EMT. halofuginone 28-40 transforming growth factor beta 1 Sus scrofa 62-71 31817562-3 2019 We activated GCN-2 kinase with halofuginone or tryptophanol, and assessed the impact of this intervention on glucose transporter-1, glucose transporter-3, and sodium-glucose cotransporter-1, glucose influx, reactive oxygen species (ROS), and the events that result in glucotoxicity. halofuginone 31-43 eukaryotic translation initiation factor 2 alpha kinase 4 Homo sapiens 13-18 31817562-8 2019 Halofuginone and tryptophanol inhibited all of the above high glucose-induced alterations, indicating that activation of GCN-2 kinase ameliorates glucotoxicity in human peritoneal mesothelial cells, preserves their integrity, and prevents MMT. halofuginone 0-12 eukaryotic translation initiation factor 2 alpha kinase 4 Homo sapiens 121-126 31719173-4 2019 HF enhanced the formation of germinal centers (GCs) and increased the production of the cytokine IL-10 in the secondary lymphoid organs of vaccinated mice. halofuginone 0-2 interleukin 10 Mus musculus 97-102 31719173-6 2019 The increased abundance of IL-10 in HF-preconditioned mice correlated with enhanced GC responses and may promote the establishment of long-lived plasma cells that secrete antigen-specific, high-affinity antibodies. halofuginone 36-38 interleukin 10 Mus musculus 27-32 30916359-0 2019 miR-31 shuttled by halofuginone-induced exosomes suppresses MFC-7 cell proliferation by modulating the HDAC2/cell cycle signaling axis. halofuginone 19-31 microRNA 31 Homo sapiens 0-6 30916359-0 2019 miR-31 shuttled by halofuginone-induced exosomes suppresses MFC-7 cell proliferation by modulating the HDAC2/cell cycle signaling axis. halofuginone 19-31 histone deacetylase 2 Homo sapiens 103-108 31046771-0 2019 Amino acid response by Halofuginone in Cancer cells triggers autophagy through proteasome degradation of mTOR. halofuginone 23-35 mechanistic target of rapamycin kinase Homo sapiens 105-109 31046771-4 2019 METHODS: As an inducer of the AAR, we used halofuginone (HF), an alkaloid that binds to the prolyl-tRNA synthetase thus mimicking the unavailability of proline (PRO). halofuginone 43-55 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 92-114 31046771-4 2019 METHODS: As an inducer of the AAR, we used halofuginone (HF), an alkaloid that binds to the prolyl-tRNA synthetase thus mimicking the unavailability of proline (PRO). halofuginone 57-59 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 92-114 30773881-1 2019 We have previously identified the cytoplasmic prolyl tRNA synthetase in Plasmodium falciparum as the functional target of the natural product febrifugine and its synthetic analogue halofuginone (HFG), one of the most potent antimalarials discovered to date. halofuginone 195-198 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 46-68 28986385-5 2017 Four modes of actions of halofuginone against fibrosis have been presented: 1) Inhibition of mothers against decapentaplegic homolog 3 (Smad3) phosphorylation downstream of the TGF-beta signaling pathway, 2) reduction of collagen amounts, 3) decreases in ECM protein, and 4) selective prevention of Th17 cell differentiation. halofuginone 25-37 SMAD family member 3 Homo sapiens 93-134 30839497-0 2019 Halofuginone protects HUVECs from H2O2-induced injury by modulating VEGF/JNK signaling pathway. halofuginone 0-12 vascular endothelial growth factor A Homo sapiens 68-72 30839497-0 2019 Halofuginone protects HUVECs from H2O2-induced injury by modulating VEGF/JNK signaling pathway. halofuginone 0-12 mitogen-activated protein kinase 8 Homo sapiens 73-76 30839497-9 2019 Finally, it was shown that halofuginone upregulated VEGF expressions, which functioned by inhibiting sustained JNK activation, thus protecting HUVECs. halofuginone 27-39 vascular endothelial growth factor A Homo sapiens 52-56 30839497-9 2019 Finally, it was shown that halofuginone upregulated VEGF expressions, which functioned by inhibiting sustained JNK activation, thus protecting HUVECs. halofuginone 27-39 mitogen-activated protein kinase 8 Homo sapiens 111-114 30839497-10 2019 CONCLUSION: Halofuginone has powerful effects in protecting HUVECs from H2O2-induced apoptosis, via upregulating VEGF and inhibiting overactivated JNK phosphorylation. halofuginone 12-24 vascular endothelial growth factor A Homo sapiens 113-117 30839497-10 2019 CONCLUSION: Halofuginone has powerful effects in protecting HUVECs from H2O2-induced apoptosis, via upregulating VEGF and inhibiting overactivated JNK phosphorylation. halofuginone 12-24 mitogen-activated protein kinase 8 Homo sapiens 147-150 29231257-0 2018 Halofuginone-induced autophagy suppresses the migration and invasion of MCF-7 cells via regulation of STMN1 and p53. halofuginone 0-12 stathmin 1 Homo sapiens 102-107 29231257-0 2018 Halofuginone-induced autophagy suppresses the migration and invasion of MCF-7 cells via regulation of STMN1 and p53. halofuginone 0-12 tumor protein p53 Homo sapiens 112-115 29621237-3 2018 Here, we show that activation of AAR pharmacologically by Halofuginone (HF) significantly inhibits production of the proinflammatory cytokine interleukin 1beta (IL-1beta) and provides protection from intestinal inflammation in mice. halofuginone 58-70 interleukin 1 beta Mus musculus 142-159 29621237-3 2018 Here, we show that activation of AAR pharmacologically by Halofuginone (HF) significantly inhibits production of the proinflammatory cytokine interleukin 1beta (IL-1beta) and provides protection from intestinal inflammation in mice. halofuginone 58-70 interleukin 1 beta Mus musculus 161-169 29771357-0 2018 A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice. halofuginone 23-35 synaptotagmin VII Mus musculus 59-74 29771357-0 2018 A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice. halofuginone 23-35 dysferlin Mus musculus 101-110 29771357-3 2018 A hypo-osmotic shock assay on myotubes derived from wild-type (Wt) and dysferlin-null (dysf-/-) mice revealed that pre-treatment with halofuginone reduces the percentage of membrane-ruptured myotubes only in dysf-/- myotubes. halofuginone 134-146 dysferlin Mus musculus 71-80 29771357-3 2018 A hypo-osmotic shock assay on myotubes derived from wild-type (Wt) and dysferlin-null (dysf-/-) mice revealed that pre-treatment with halofuginone reduces the percentage of membrane-ruptured myotubes only in dysf-/- myotubes. halofuginone 134-146 dysferlin Mus musculus 71-75 29771357-3 2018 A hypo-osmotic shock assay on myotubes derived from wild-type (Wt) and dysferlin-null (dysf-/-) mice revealed that pre-treatment with halofuginone reduces the percentage of membrane-ruptured myotubes only in dysf-/- myotubes. halofuginone 134-146 dysferlin Mus musculus 87-91 29771357-4 2018 In laser-induced injury of isolated myofibers, halofuginone decreased the amount of FM1-43 at the injury site of dysf-/- myofibers while having no effect on Wt myofibers. halofuginone 47-59 dysferlin Mus musculus 113-117 29771357-5 2018 These results implicate halofuginone in ameliorating muscle-cell membrane integrity in dysf-/- mice. halofuginone 24-36 dysferlin Mus musculus 87-91 29771357-6 2018 Halofuginone increased lysosome scattering across the cytosol of dysf-/- primary myoblasts, in a protein kinase/extracellular signal-regulated protein kinase and phosphoinositide 3 kinase/Akt-dependent manner, in agreement with an elevation in lysosomal exocytotic activity in these cells. halofuginone 0-12 dysferlin Mus musculus 65-69 29771357-6 2018 Halofuginone increased lysosome scattering across the cytosol of dysf-/- primary myoblasts, in a protein kinase/extracellular signal-regulated protein kinase and phosphoinositide 3 kinase/Akt-dependent manner, in agreement with an elevation in lysosomal exocytotic activity in these cells. halofuginone 0-12 thymoma viral proto-oncogene 1 Mus musculus 188-191 29771357-8 2018 While halofuginone did not affect patch-repair-complex key proteins, it further enhanced Syt-7 levels and its spread across the cytosol in dysf-/- myofibers and muscle tissue, and increased its co-localization with lysosomes. halofuginone 6-18 synaptotagmin VII Mus musculus 89-94 29771357-8 2018 While halofuginone did not affect patch-repair-complex key proteins, it further enhanced Syt-7 levels and its spread across the cytosol in dysf-/- myofibers and muscle tissue, and increased its co-localization with lysosomes. halofuginone 6-18 dysferlin Mus musculus 139-143 29771357-9 2018 Together, the data imply a novel role for halofuginone in membrane-resealing events with Syt-7 possibly taking part in these events. halofuginone 42-54 synaptotagmin VII Mus musculus 89-94 28986385-5 2017 Four modes of actions of halofuginone against fibrosis have been presented: 1) Inhibition of mothers against decapentaplegic homolog 3 (Smad3) phosphorylation downstream of the TGF-beta signaling pathway, 2) reduction of collagen amounts, 3) decreases in ECM protein, and 4) selective prevention of Th17 cell differentiation. halofuginone 25-37 SMAD family member 3 Homo sapiens 136-141 29065190-2 2017 Halofuginone (HF) is a well-known anti-fibrosis agent in preclinical and clinical studies which exerts its effect via inhibition of TGF-beta/Smad3 signaling pathway. halofuginone 0-12 SMAD family member 3 Mus musculus 141-146 28501621-2 2017 An ATP-dependent PRS inhibitor, halofuginone, was shown to suppress autoimmune responses, suggesting that the inhibition of PRS is a potential therapeutic approach for inflammatory diseases. halofuginone 32-44 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 17-20 29156807-0 2017 Halofuginone inhibits TGF-beta/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 22-30 29156807-3 2017 Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGFbeta and BMP-signaling. halofuginone 25-37 transforming growth factor beta 1 Homo sapiens 152-159 29156807-4 2017 Halofuginone blocked TGF-beta-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-beta-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-beta-regulated metastatic genes. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 21-29 29156807-4 2017 Halofuginone blocked TGF-beta-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-beta-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-beta-regulated metastatic genes. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 92-100 29156807-4 2017 Halofuginone blocked TGF-beta-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-beta-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-beta-regulated metastatic genes. halofuginone 0-12 SMAD family member 1 Homo sapiens 109-113 29156807-4 2017 Halofuginone blocked TGF-beta-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-beta-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-beta-regulated metastatic genes. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 92-100 29156807-5 2017 Halofuginone increased inhibitory Smad7-mRNA and reduced TGF-beta-receptor II protein. halofuginone 0-12 SMAD family member 7 Mus musculus 34-39 29156807-5 2017 Halofuginone increased inhibitory Smad7-mRNA and reduced TGF-beta-receptor II protein. halofuginone 0-12 transforming growth factor, beta receptor II Mus musculus 57-77 29156807-6 2017 Proline supplementation but not Smad7-knockdown reversed halofuginone-inhibition of TGF-beta-signaling. halofuginone 57-69 transforming growth factor, beta 1 Mus musculus 84-92 29156807-8 2017 Treatment of MDA-MB-231 and PC3 cells with halofuginone reduced the BMP-Smad-reporter (BRE)4, Smad1/5/8-phosphorylation and mRNA of the BMP-regulated gene Id-1. halofuginone 43-55 SMAD family member 1 Homo sapiens 94-101 29156807-9 2017 Halofuginone decreased immunostaining of phospho-Smad2/3 and phospho-Smad1/5/8 in cancer cells in vivo. halofuginone 0-12 SMAD family member 1 Homo sapiens 69-76 29066866-0 2017 Halofuginone ameliorates inflammation in severe acute hepatitis B virus (HBV)-infected SD rats through AMPK activation. halofuginone 0-12 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 103-107 28501621-2 2017 An ATP-dependent PRS inhibitor, halofuginone, was shown to suppress autoimmune responses, suggesting that the inhibition of PRS is a potential therapeutic approach for inflammatory diseases. halofuginone 32-44 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 124-127 28501621-9 2017 The results demonstrated the different inhibitory and binding mode of pyrazinamide PRS inhibitors from preceding halofuginone. halofuginone 113-125 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 83-86 28501621-10 2017 Furthermore, the PRS inhibitor inhibited intracellular protein synthesis via a different mode than halofuginone. halofuginone 99-111 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 17-20 28501621-13 2017 Thus, the series of PRS inhibitors are considered to be applicable to further development with differentiation from preceding halofuginone. halofuginone 126-138 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 20-23 28082118-8 2017 Inhibition of fibrosis by halofuginone, an antifibrotic agent, resulted in a major decrease in moesin levels in the muscles of DMD and CMD mice. halofuginone 26-38 moesin Mus musculus 95-101 28492544-2 2017 Our previous study found that halofuginone (HF) exerts anticancer activity in colorectal cancer (CRC) by downregulating Akt/mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway. halofuginone 30-42 thymoma viral proto-oncogene 1 Mus musculus 120-123 28492544-2 2017 Our previous study found that halofuginone (HF) exerts anticancer activity in colorectal cancer (CRC) by downregulating Akt/mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway. halofuginone 30-42 CREB regulated transcription coactivator 1 Mus musculus 124-130 28487390-4 2017 Our aim was to investigate the effects of halofuginone, a prolyl-tRNA synthetase inhibitor, on the AAR pathway in cardiac fibroblasts, cardiomyocytes, and in mouse models of cardiac stress and failure. halofuginone 42-54 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 58-80 28487390-5 2017 METHODS AND RESULTS: Consistent with its ability to inhibit prolyl-tRNA synthetase, halofuginone elicited a general control nonderepressible 2-dependent activation of the AAR pathway in cardiac fibroblasts as evidenced by activation of known AAR target genes, broad regulation of the transcriptome and proteome, and reversal by l-proline supplementation. halofuginone 84-96 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 60-82 28487390-5 2017 METHODS AND RESULTS: Consistent with its ability to inhibit prolyl-tRNA synthetase, halofuginone elicited a general control nonderepressible 2-dependent activation of the AAR pathway in cardiac fibroblasts as evidenced by activation of known AAR target genes, broad regulation of the transcriptome and proteome, and reversal by l-proline supplementation. halofuginone 84-96 eukaryotic translation initiation factor 2 alpha kinase 4 Homo sapiens 108-142 28487390-8 2017 In human cardiac fibroblasts, halofuginone profoundly reduced collagen deposition in a general control nonderepressible 2-dependent manner and suppressed the extracellular matrix proteome. halofuginone 30-42 eukaryotic translation initiation factor 2 alpha kinase 4 Homo sapiens 87-121 28487390-9 2017 In human induced pluripotent stem cell-derived cardiomyocytes, halofuginone blocked gene expression associated with endothelin-1-mediated activation of pathologic hypertrophy and restored autophagy in a general control nonderepressible 2/eIF2alpha-dependent manner. halofuginone 63-75 endothelin 1 Homo sapiens 116-128 28487390-9 2017 In human induced pluripotent stem cell-derived cardiomyocytes, halofuginone blocked gene expression associated with endothelin-1-mediated activation of pathologic hypertrophy and restored autophagy in a general control nonderepressible 2/eIF2alpha-dependent manner. halofuginone 63-75 eukaryotic translation initiation factor 2 alpha kinase 4 Homo sapiens 203-237 28487390-9 2017 In human induced pluripotent stem cell-derived cardiomyocytes, halofuginone blocked gene expression associated with endothelin-1-mediated activation of pathologic hypertrophy and restored autophagy in a general control nonderepressible 2/eIF2alpha-dependent manner. halofuginone 63-75 eukaryotic translation initiation factor 2A Homo sapiens 238-247 27878913-14 2017 Halofuginone administered orally for 10 weeks prevented elastin loss and demonstrated a trend of reducing collagen density post-injury. halofuginone 0-12 elastin Ovis aries 56-63 28039084-0 2017 Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. halofuginone 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 75-79 28039084-8 2017 We found that application of the less-toxic derivative halofuginone in a low dose range rapidly reduced NRF2 protein levels. halofuginone 55-67 NFE2 like bZIP transcription factor 2 Homo sapiens 104-108 28039084-9 2017 Halofuginone induced a cellular amino acid starvation response that repressed global protein synthesis and rapidly depleted NRF2. halofuginone 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 124-128 28039084-11 2017 These results provide preclinical proof-of-concept evidence for halofuginone as an NRF2 inhibitor applicable to treatment of chemo- and radio-resistant forms of cancer. halofuginone 64-76 NFE2 like bZIP transcription factor 2 Homo sapiens 83-87 28013187-0 2017 Halofuginone inhibits TNF-alpha-induced the migration and proliferation of fibroblast-like synoviocytes from rheumatoid arthritis patients. halofuginone 0-12 tumor necrosis factor Homo sapiens 22-31 28013187-7 2017 To gain insight into the molecular mechanisms, we evaluated the effect of halofuginone on the MAPK and AKT pathways. halofuginone 74-86 AKT serine/threonine kinase 1 Homo sapiens 103-106 28013187-8 2017 Our results indicated that halofuginone inhibited the activity of MAPK and AKT. halofuginone 27-39 AKT serine/threonine kinase 1 Homo sapiens 75-78 28013187-9 2017 Taken together, these results suggest that halofuginone may protect against joint destruction in RA by regulating synoviocyte migration, invasion and cell proliferation by inhibiting MAPK and AKT activation. halofuginone 43-55 AKT serine/threonine kinase 1 Homo sapiens 192-195 27533085-3 2016 This study investigated the inhibitory effects of halofuginone, a plant-derived alkaloid that has been shown to inhibit TGF-beta1 signaling, on radiation-induced EMT and explored the underlying mechanisms using a Lewis lung carcinoma (LLC) xenograft model. halofuginone 50-62 transforming growth factor, beta 1 Mus musculus 120-129 27533085-8 2016 In addition, TGF-beta1/Smad signaling was activated by radiotherapy and the mRNA expression of Twist and Snail was elevated; this effect was reversed by halofuginone or the TGF-beta1 inhibitor SB431542. halofuginone 153-165 transforming growth factor, beta 1 Mus musculus 13-22 27533085-8 2016 In addition, TGF-beta1/Smad signaling was activated by radiotherapy and the mRNA expression of Twist and Snail was elevated; this effect was reversed by halofuginone or the TGF-beta1 inhibitor SB431542. halofuginone 153-165 snail family zinc finger 1 Mus musculus 105-110 27533085-9 2016 Our results demonstrate that halofuginone inhibits radiation-induced EMT, and suggest that suppression of TGF-beta1 signaling may be responsible for this effect. halofuginone 29-41 transforming growth factor, beta 1 Mus musculus 106-115 27687492-10 2016 The TGF-beta/Smad pathway of fibrosis and opacity was inhibited by IGF-1, and further with SAHA in particular, and with halofuginone. halofuginone 120-132 transforming growth factor beta 1 Homo sapiens 4-12 27369778-5 2016 Pharmacologic induction of IFNAR1 ubiquitination and degradation by an antiprotozoal agent halofuginone also relieved psoriasiform inflammation in wild-type but not in Ifnar1(SA) mice. halofuginone 91-103 interferon (alpha and beta) receptor 1 Mus musculus 27-33 27687492-10 2016 The TGF-beta/Smad pathway of fibrosis and opacity was inhibited by IGF-1, and further with SAHA in particular, and with halofuginone. halofuginone 120-132 SMAD family member 7 Homo sapiens 13-17 26470720-8 2016 Halofuginone reduced collagen X (Col X), matrix metalloproteinase-13 and A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS 5) and increased lubricin, collagen II and aggrecan. halofuginone 0-12 matrix metallopeptidase 13 Rattus norvegicus 41-68 26470720-8 2016 Halofuginone reduced collagen X (Col X), matrix metalloproteinase-13 and A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS 5) and increased lubricin, collagen II and aggrecan. halofuginone 0-12 ADAM metallopeptidase with thrombospondin type 1 motif, 5 Rattus norvegicus 73-137 26470720-8 2016 Halofuginone reduced collagen X (Col X), matrix metalloproteinase-13 and A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS 5) and increased lubricin, collagen II and aggrecan. halofuginone 0-12 ADAM metallopeptidase with thrombospondin type 1 motif, 5 Rattus norvegicus 139-147 26470720-8 2016 Halofuginone reduced collagen X (Col X), matrix metalloproteinase-13 and A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS 5) and increased lubricin, collagen II and aggrecan. halofuginone 0-12 proteoglycan 4 Rattus norvegicus 163-171 26470720-10 2016 We found that halofuginone exerted protective effects in part by suppressing Th17-induced osteoclastic bone resorption, inhibiting Smad2/3-dependent TGF-beta signalling to restore coupled bone remodelling and attenuating excessive angiogenesis in subchondral bone. halofuginone 14-26 SMAD family member 2 Rattus norvegicus 131-138 27197570-2 2016 Here, we report that halofuginone (HF), an antiparasitic drug, attenuates dextran sulfate sodium (DSS)-induced colitis in mice, as represented by attenuating the disease activity index, inhibiting colonic shortening, ameliorating colonic lesions and histological signs of damage, reducing colonic myeloperoxidase activity, and suppressing the production of pro-inflammatory cytokines in colon tissue. halofuginone 21-33 myeloperoxidase Mus musculus 297-312 27385212-0 2016 Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. halofuginone 0-12 cyclin dependent kinase inhibitor 1A Homo sapiens 100-107 27385212-0 2016 Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. halofuginone 0-12 cyclin dependent kinase inhibitor 1B Homo sapiens 112-119 26160839-0 2015 Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism. halofuginone 0-12 AKT serine/threonine kinase 1 Homo sapiens 70-73 26454207-5 2016 In cultures of myofibers and myoblasts isolated from dysf(-/-) mice, halofuginone reduced Bax and induced Bcl2 expression levels and induced Akt phosphorylation in a time-dependent manner. halofuginone 69-81 BCL2-associated X protein Mus musculus 90-93 26454207-5 2016 In cultures of myofibers and myoblasts isolated from dysf(-/-) mice, halofuginone reduced Bax and induced Bcl2 expression levels and induced Akt phosphorylation in a time-dependent manner. halofuginone 69-81 B cell leukemia/lymphoma 2 Mus musculus 106-110 26454207-5 2016 In cultures of myofibers and myoblasts isolated from dysf(-/-) mice, halofuginone reduced Bax and induced Bcl2 expression levels and induced Akt phosphorylation in a time-dependent manner. halofuginone 69-81 thymoma viral proto-oncogene 1 Mus musculus 141-144 26454207-6 2016 Addition of an inhibitor of the phosphinositide-3-kinase/Akt pathway reversed the halofuginone-induced cell survival, suggesting this pathway"s involvement in mediating halofuginone"s effects on survival. halofuginone 82-94 thymoma viral proto-oncogene 1 Mus musculus 57-60 26454207-6 2016 Addition of an inhibitor of the phosphinositide-3-kinase/Akt pathway reversed the halofuginone-induced cell survival, suggesting this pathway"s involvement in mediating halofuginone"s effects on survival. halofuginone 169-181 thymoma viral proto-oncogene 1 Mus musculus 57-60 26884857-6 2015 And we found that halofuginone inhibits tumor cell cycle possibly by up-regulating p15 and p21 of expression. halofuginone 18-30 cyclin dependent kinase inhibitor 2B Homo sapiens 83-86 26884857-6 2015 And we found that halofuginone inhibits tumor cell cycle possibly by up-regulating p15 and p21 of expression. halofuginone 18-30 H3 histone pseudogene 16 Homo sapiens 91-94 26884857-7 2015 Then, we found that the proportion of cleaved PARP, caspase-3, 8 and 9 in HepG2 cells increased after halofuginone treatment. halofuginone 102-114 poly(ADP-ribose) polymerase 1 Homo sapiens 46-50 26884857-7 2015 Then, we found that the proportion of cleaved PARP, caspase-3, 8 and 9 in HepG2 cells increased after halofuginone treatment. halofuginone 102-114 caspase 3 Homo sapiens 52-61 26884857-8 2015 And the results showed that halofuginone down-regulated Mcl-1 and c-IAP1 expression. halofuginone 28-40 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 56-61 26884857-8 2015 And the results showed that halofuginone down-regulated Mcl-1 and c-IAP1 expression. halofuginone 28-40 baculoviral IAP repeat containing 2 Homo sapiens 66-72 26884857-9 2015 Finally, our results showed halofuginone regulated the activities of JNK and MEK/ERK signaling pathways in hepatocellular carcinoma cells. halofuginone 28-40 mitogen-activated protein kinase 8 Homo sapiens 69-72 26884857-9 2015 Finally, our results showed halofuginone regulated the activities of JNK and MEK/ERK signaling pathways in hepatocellular carcinoma cells. halofuginone 28-40 mitogen-activated protein kinase kinase 7 Homo sapiens 77-80 27021682-0 2016 Halofuginone alleviates acute viral myocarditis in suckling BALB/c mice by inhibiting TGF-beta1. halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 86-95 26787621-0 2016 Halofuginone treatment reduces interleukin-17A and ameliorates features of chronic lung allograft dysfunction in a mouse orthotopic lung transplant model. halofuginone 0-12 interleukin 17A Mus musculus 31-46 26787621-8 2016 Immunofluorescent staining for IL-17A demonstrated a decreased number and frequency of IL-17A-positive cells in halofuginone-treated lung grafts on Day 28, as compared with controls. halofuginone 112-124 interleukin 17A Mus musculus 31-37 26787621-8 2016 Immunofluorescent staining for IL-17A demonstrated a decreased number and frequency of IL-17A-positive cells in halofuginone-treated lung grafts on Day 28, as compared with controls. halofuginone 112-124 interleukin 17A Mus musculus 87-93 26787621-9 2016 Halofuginone treatment also decreased IL-17A and IL-22 transcripts at Day 14, transforming growth factor-beta1 and matrix metalloproteinase-2 transcripts at Days 14 and 28. halofuginone 0-12 interleukin 17A Mus musculus 38-44 26787621-9 2016 Halofuginone treatment also decreased IL-17A and IL-22 transcripts at Day 14, transforming growth factor-beta1 and matrix metalloproteinase-2 transcripts at Days 14 and 28. halofuginone 0-12 interleukin 22 Mus musculus 49-54 26787621-9 2016 Halofuginone treatment also decreased IL-17A and IL-22 transcripts at Day 14, transforming growth factor-beta1 and matrix metalloproteinase-2 transcripts at Days 14 and 28. halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 70-110 26787621-10 2016 CONCLUSION: The beneficial effect of halofuginone on development of airway and lung parenchymal fibrosis in the mouse lung transplant model highlights the important role of IL-17A in CLAD and merits further pre-clinical and clinical studies. halofuginone 37-49 interleukin 17A Mus musculus 173-179 26664138-0 2015 Inhibition of TGF-beta signaling with halofuginone can enhance the antitumor effect of irradiation in Lewis lung cancer. halofuginone 38-50 transforming growth factor, beta 1 Mus musculus 14-22 26664138-1 2015 PURPOSE: It was reported that halofuginone has inhibitory effects on transforming growth factor-beta (TGF-beta) signaling pathway. halofuginone 30-42 transforming growth factor, beta 1 Mus musculus 102-110 26664138-11 2015 The addition of halofuginone can significantly inhibit the migratory and invasive trend induced by irradiation, and the TGF-beta pathway was also inhibited. halofuginone 16-28 transforming growth factor, beta 1 Mus musculus 120-128 26524063-2 2015 METHODS: In a murine GVHD model of C57BL/6 (H-2(b)), a low dose of halofuginone (HF) was applied for treating the recipients in order to result in Th1/Th17 imbalance. halofuginone 67-79 negative elongation factor complex member C/D, Th1l Mus musculus 147-150 26015394-4 2015 In the mdx mice diaphragm (n = 6/group), inhibition of fibrosis by halofuginone resulted in increases in the levels of utrophin. halofuginone 67-79 utrophin Mus musculus 119-127 26160839-0 2015 Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism. halofuginone 0-12 CREB regulated transcription coactivator 1 Mus musculus 74-80 26160839-2 2015 Here, we present for the first time that halofuginone (HF) treatment inhibits colorectal cancer (CRC) growth both in vitro and in vivo through regulation of Akt/mTORC1 signaling pathway. halofuginone 41-53 AKT serine/threonine kinase 1 Homo sapiens 157-160 26160839-2 2015 Here, we present for the first time that halofuginone (HF) treatment inhibits colorectal cancer (CRC) growth both in vitro and in vivo through regulation of Akt/mTORC1 signaling pathway. halofuginone 41-53 CREB regulated transcription coactivator 1 Mus musculus 161-167 26099922-0 2015 Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. halofuginone 0-12 SMAD family member 2 Mus musculus 41-47 26099922-1 2015 BACKGROUND: Halofuginone (HF) is a low-molecular-weight alkaloid that has been demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-beta (TGF-beta) function and, to present antiangiogenic, antiproliferative and proapoptotic properties in several solid tumor models. halofuginone 12-24 matrix metallopeptidase 2 Mus musculus 131-136 26099922-1 2015 BACKGROUND: Halofuginone (HF) is a low-molecular-weight alkaloid that has been demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-beta (TGF-beta) function and, to present antiangiogenic, antiproliferative and proapoptotic properties in several solid tumor models. halofuginone 12-24 transforming growth factor, beta 1 Mus musculus 168-176 25817387-0 2015 Structure of Prolyl-tRNA Synthetase-Halofuginone Complex Provides Basis for Development of Drugs against Malaria and Toxoplasmosis. halofuginone 36-48 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 13-35 26015407-2 2015 Because we recently demonstrated that TGF-beta/Smad cascade plays a crucial role in osteosarcoma metastatic progression, we investigated the effect of halofuginone, identified as an inhibitor of the TGF-beta/Smad3 cascade, on osteosarcoma progression. halofuginone 151-163 transforming growth factor beta 1 Homo sapiens 199-207 26015407-2 2015 Because we recently demonstrated that TGF-beta/Smad cascade plays a crucial role in osteosarcoma metastatic progression, we investigated the effect of halofuginone, identified as an inhibitor of the TGF-beta/Smad3 cascade, on osteosarcoma progression. halofuginone 151-163 SMAD family member 3 Homo sapiens 208-213 26015407-5 2015 In vitro experiments demonstrated that halofuginone decreases cell viability mainly by its ability to induce caspase-3 dependent cell apoptosis. halofuginone 39-51 caspase 3 Homo sapiens 109-118 26015407-6 2015 Moreover, halofuginone inhibits the TGF-beta/Smad3 cascade and the response of TGF-beta key targets involved in the metastases dissemination process such as MMP-2. halofuginone 10-22 transforming growth factor beta 1 Homo sapiens 36-44 26015407-6 2015 Moreover, halofuginone inhibits the TGF-beta/Smad3 cascade and the response of TGF-beta key targets involved in the metastases dissemination process such as MMP-2. halofuginone 10-22 SMAD family member 3 Homo sapiens 45-50 26015407-6 2015 Moreover, halofuginone inhibits the TGF-beta/Smad3 cascade and the response of TGF-beta key targets involved in the metastases dissemination process such as MMP-2. halofuginone 10-22 transforming growth factor beta 1 Homo sapiens 79-87 26015407-6 2015 Moreover, halofuginone inhibits the TGF-beta/Smad3 cascade and the response of TGF-beta key targets involved in the metastases dissemination process such as MMP-2. halofuginone 10-22 matrix metallopeptidase 2 Homo sapiens 157-162 25569515-3 2015 At present two modes of halofuginone actions have been described: (1) Inhibition of Smad3 phosphorylation downstream of the TGFbeta signaling pathway results in inhibition of fibroblasts-to-myofibroblasts transition and fibrosis. halofuginone 24-36 SMAD family member 3 Homo sapiens 84-89 25356039-6 2014 The high efficacy of halofuginone in reducing the fibrosis that affects tumor growth and tissue regeneration is probably due to its dual role in inhibiting the signaling pathway of transforming growth factor beta, on the one hand, and inhibiting the development of Th17 cells, on the other hand. halofuginone 21-33 transforming growth factor beta 1 Homo sapiens 181-212 24845795-4 2014 METHODS: We applied a murine GVHD model of C57BL/6 (H-2(b)) donor to BALB/c (H-2(d)) recipient by treating the recipients with low dose of halofuginone (HF), which is competent in selectively inhibiting Th17 differentiation and facilitating Th1 differentiation. halofuginone 139-151 negative elongation factor complex member C/D Homo sapiens 203-206 25074254-7 2014 Furthermore, halofuginone at 50 nmol/L effectively blocked Smad3 phosphorylation in smooth muscle cells, which is known to promote smooth muscle cell proliferation, migration, and IH, but halofuginone had no effect on phospho-Smad3 in endothelial cells. halofuginone 13-25 SMAD family member 3 Rattus norvegicus 59-64 23845969-0 2014 Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. halofuginone 0-12 SMAD family member 3 Homo sapiens 28-33 24703880-1 2014 Halofuginone has been shown to prevent fibrosis via the transforming growth factor-beta/Smad3 pathway in muscular dystrophies. halofuginone 0-12 SMAD family member 3 Mus musculus 88-93 24703880-5 2014 Halofuginone treatment of mdx mice reduced the apoptotic nuclei number in the diaphragm, together with reduction in Bax and induction in Bcl2 levels in myofibers isolated from these mice. halofuginone 0-12 BCL2-associated X protein Mus musculus 116-119 24703880-5 2014 Halofuginone treatment of mdx mice reduced the apoptotic nuclei number in the diaphragm, together with reduction in Bax and induction in Bcl2 levels in myofibers isolated from these mice. halofuginone 0-12 B cell leukemia/lymphoma 2 Mus musculus 137-141 24703880-8 2014 Inhibition of apoptosis or staurosporine-induced apoptosis by halofuginone in mdx primary myoblasts and C2 myogenic cell line, respectively, was reflected by less pyknotic/apoptotic cells and reduced Bax expression. halofuginone 62-74 BCL2-associated X protein Mus musculus 200-203 24782183-8 2014 RESULTS: Treatment with halofuginone suppressed the development of autoimmune arthritis and reciprocally regulated Th17 cells and FoxP3+ Treg cells. halofuginone 24-36 forkhead box P3 Mus musculus 130-135 24782183-9 2014 These effects of halofuginone on Th17 differentiation involved increased signaling of ERK and reduction of STAT-3 and NF-ATc1 expression. halofuginone 17-29 mitogen-activated protein kinase 1 Mus musculus 86-89 24782183-9 2014 These effects of halofuginone on Th17 differentiation involved increased signaling of ERK and reduction of STAT-3 and NF-ATc1 expression. halofuginone 17-29 signal transducer and activator of transcription 3 Mus musculus 107-113 24782183-9 2014 These effects of halofuginone on Th17 differentiation involved increased signaling of ERK and reduction of STAT-3 and NF-ATc1 expression. halofuginone 17-29 nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 Mus musculus 118-125 24782183-11 2014 In addition, halofuginone prevented the formation and activity of osteoclasts through suppression of transcription factors, such as activator protein 1 and NF-ATc1, and inhibited cell cycle arrest by the committed osteoclast precursors via expression of Ccnd1 encoding cyclin D1. halofuginone 13-25 jun proto-oncogene Mus musculus 132-151 24782183-11 2014 In addition, halofuginone prevented the formation and activity of osteoclasts through suppression of transcription factors, such as activator protein 1 and NF-ATc1, and inhibited cell cycle arrest by the committed osteoclast precursors via expression of Ccnd1 encoding cyclin D1. halofuginone 13-25 nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 Mus musculus 156-163 24782183-11 2014 In addition, halofuginone prevented the formation and activity of osteoclasts through suppression of transcription factors, such as activator protein 1 and NF-ATc1, and inhibited cell cycle arrest by the committed osteoclast precursors via expression of Ccnd1 encoding cyclin D1. halofuginone 13-25 cyclin D1 Mus musculus 254-259 24782183-11 2014 In addition, halofuginone prevented the formation and activity of osteoclasts through suppression of transcription factors, such as activator protein 1 and NF-ATc1, and inhibited cell cycle arrest by the committed osteoclast precursors via expression of Ccnd1 encoding cyclin D1. halofuginone 13-25 cyclin D1 Mus musculus 269-278 23845969-0 2014 Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 62-69 22971531-5 2012 After injected with halofuginone, we observed a decrease in the number of CD4(+) interleukin (IL)-17(+) cells and a parallel increase in that of CD4(+) interferon (IFN)-gamma(+) cells in peripheral blood. halofuginone 20-32 CD4 antigen Mus musculus 74-77 24489094-0 2014 Halofuginone-induced amino acid starvation regulates Stat3-dependent Th17 effector function and reduces established autoimmune inflammation. halofuginone 0-12 signal transducer and activator of transcription 3 Mus musculus 53-58 24489094-4 2014 The prolyl-tRNA synthetase inhibitor halofuginone blocks IL-23-induced Stat3 phosphorylation and IL-23-dependent proinflammatory cytokine expression in endogenous CCR6(+) Th17 cells via activation of the amino acid starvation response (AAR) pathway. halofuginone 37-49 interleukin 23, alpha subunit p19 Mus musculus 57-62 24489094-4 2014 The prolyl-tRNA synthetase inhibitor halofuginone blocks IL-23-induced Stat3 phosphorylation and IL-23-dependent proinflammatory cytokine expression in endogenous CCR6(+) Th17 cells via activation of the amino acid starvation response (AAR) pathway. halofuginone 37-49 signal transducer and activator of transcription 3 Mus musculus 71-76 24100331-0 2013 Conformational changes in human prolyl-tRNA synthetase upon binding of the substrates proline and ATP and the inhibitor halofuginone. halofuginone 120-132 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 32-54 24100331-2 2013 Halofuginone (HF), a coccidiostat used in veterinary medicine, exerts its effects by acting as a high-affinity inhibitor of the enzyme glutamyl-prolyl-tRNA synthetase (EPRS). halofuginone 0-12 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 135-166 24100331-2 2013 Halofuginone (HF), a coccidiostat used in veterinary medicine, exerts its effects by acting as a high-affinity inhibitor of the enzyme glutamyl-prolyl-tRNA synthetase (EPRS). halofuginone 14-16 glutamyl-prolyl-tRNA synthetase 1 Homo sapiens 135-166 22373656-7 2013 Halofuginone treatment was found to reduce oxidative I/R injury and improve renal function in the rat kidney, as evidenced by reduced generation of reactive oxygen species, depressed lipid peroxidation and myeloperoxidase activity, and increased glutathione levels. halofuginone 0-12 myeloperoxidase Rattus norvegicus 206-221 24489094-4 2014 The prolyl-tRNA synthetase inhibitor halofuginone blocks IL-23-induced Stat3 phosphorylation and IL-23-dependent proinflammatory cytokine expression in endogenous CCR6(+) Th17 cells via activation of the amino acid starvation response (AAR) pathway. halofuginone 37-49 interleukin 23, alpha subunit p19 Mus musculus 97-102 24489094-4 2014 The prolyl-tRNA synthetase inhibitor halofuginone blocks IL-23-induced Stat3 phosphorylation and IL-23-dependent proinflammatory cytokine expression in endogenous CCR6(+) Th17 cells via activation of the amino acid starvation response (AAR) pathway. halofuginone 37-49 chemokine (C-C motif) receptor 6 Mus musculus 163-167 24173318-0 2014 Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. halofuginone 0-12 matrix metallopeptidase 9 Homo sapiens 103-129 23274062-6 2013 Halofuginone, an inhibitor of Smad3 phosphorylation downstream of the transforming growth factor-beta signaling, reduced Cthrc1 levels in skeletal and cardiac muscles of mice, representing DMD, CMD, and dysferlinopathy. halofuginone 0-12 SMAD family member 3 Mus musculus 30-35 23274062-6 2013 Halofuginone, an inhibitor of Smad3 phosphorylation downstream of the transforming growth factor-beta signaling, reduced Cthrc1 levels in skeletal and cardiac muscles of mice, representing DMD, CMD, and dysferlinopathy. halofuginone 0-12 collagen triple helix repeat containing 1 Mus musculus 121-127 23275304-0 2013 Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. halofuginone 112-124 dysferlin Mus musculus 74-83 23275304-2 2013 We evaluated halofuginone efficacy in improving muscle histopathology in mice with deleted dysf transmembrane domain. halofuginone 13-25 dysferlin Mus musculus 91-95 23275304-3 2013 Quadriceps sublumbar and longissimus muscles of 9-month-old dysf-/- mice treated with halofuginone for 4 months exhibited a reduction in centrally-nucleated myofibers, inflammatory infiltrates and collagen content. halofuginone 86-98 dysferlin Mus musculus 60-64 23275304-9 2013 Halofuginone inhibited Smad3 phosphorylation and its translocation to the nucleus and increased the activity of matrix metalloproteinases 9 and 2 responsible for resolution of pre-existing collagen. halofuginone 0-12 SMAD family member 3 Mus musculus 23-28 23002206-2 2012 Halofuginone is a plant alkaloid derivative that blocks TGF-beta signaling with antiangiogenic and antiproliferative properties. halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 56-64 23002206-3 2012 Here, we show for the first time that halofuginone therapy decreases development and progression of bone metastasis caused by melanoma cells through the inhibition of TGF-beta signaling. halofuginone 38-50 transforming growth factor, beta 1 Mus musculus 167-175 23002206-4 2012 Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-beta, and TGF-beta-induced SMAD-driven transcription. halofuginone 0-12 SMAD family member 7 Mus musculus 96-100 23002206-4 2012 Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-beta, and TGF-beta-induced SMAD-driven transcription. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 125-133 23002206-4 2012 Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-beta, and TGF-beta-induced SMAD-driven transcription. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 139-147 23002206-4 2012 Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-beta, and TGF-beta-induced SMAD-driven transcription. halofuginone 0-12 SMAD family member 7 Mus musculus 156-160 23002206-5 2012 In addition, halofuginone reduced expression of TGF-beta target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. halofuginone 13-25 transforming growth factor, beta 1 Mus musculus 48-56 23002206-5 2012 In addition, halofuginone reduced expression of TGF-beta target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. halofuginone 13-25 parathyroid hormone-like peptide Mus musculus 110-115 23002206-5 2012 In addition, halofuginone reduced expression of TGF-beta target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. halofuginone 13-25 cellular communication network factor 2 Mus musculus 117-121 23002206-5 2012 In addition, halofuginone reduced expression of TGF-beta target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. halofuginone 13-25 chemokine (C-X-C motif) receptor 4 Mus musculus 123-128 23002206-5 2012 In addition, halofuginone reduced expression of TGF-beta target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. halofuginone 13-25 interleukin 11 Mus musculus 134-138 23002206-8 2012 The beneficial effects of halofuginone treatment were comparable with those observed with other anti-TGF-beta strategies, including systemic administration of SD208, a small-molecule inhibitor of TGF-beta receptor I kinase, or forced overexpression of Smad7, a negative regulator of TGF-beta signaling. halofuginone 26-38 transforming growth factor, beta 1 Mus musculus 101-109 23002206-8 2012 The beneficial effects of halofuginone treatment were comparable with those observed with other anti-TGF-beta strategies, including systemic administration of SD208, a small-molecule inhibitor of TGF-beta receptor I kinase, or forced overexpression of Smad7, a negative regulator of TGF-beta signaling. halofuginone 26-38 SMAD family member 7 Mus musculus 252-257 22885662-0 2012 Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. halofuginone 44-56 matrix metallopeptidase 2 Homo sapiens 14-40 22885662-0 2012 Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. halofuginone 44-56 early growth response 1 Homo sapiens 76-80 22885662-4 2012 We found a marked (50%) inhibition in MMP-2 gelatinolytic activity in human breast cancer MDA-MB-435 cells pretreated with as little as 50 ng/ml of halofuginone, a concentration that markedly inhibited their invasive and proliferative capacities. halofuginone 148-160 matrix metallopeptidase 2 Homo sapiens 38-43 22885662-5 2012 We further show that both early growth response 1 (Egr-1) and Nab-2 (corepressor of Egr1 activation) are upregulated by halofuginone in a dose-dependent and time-dependent (up to 5 h) manner. halofuginone 120-132 early growth response 1 Homo sapiens 26-49 22885662-5 2012 We further show that both early growth response 1 (Egr-1) and Nab-2 (corepressor of Egr1 activation) are upregulated by halofuginone in a dose-dependent and time-dependent (up to 5 h) manner. halofuginone 120-132 early growth response 1 Homo sapiens 51-56 22885662-5 2012 We further show that both early growth response 1 (Egr-1) and Nab-2 (corepressor of Egr1 activation) are upregulated by halofuginone in a dose-dependent and time-dependent (up to 5 h) manner. halofuginone 120-132 NGFI-A binding protein 2 Homo sapiens 62-67 22885662-5 2012 We further show that both early growth response 1 (Egr-1) and Nab-2 (corepressor of Egr1 activation) are upregulated by halofuginone in a dose-dependent and time-dependent (up to 5 h) manner. halofuginone 120-132 early growth response 1 Homo sapiens 84-88 22885662-7 2012 Altogether, our results identify the downstream elements (Egr-1, Nab-2, and MMP-2) by which halofuginone exerts its antitumoral effect, thereby advancing its potential therapeutic application as an anticancer drug. halofuginone 92-104 early growth response 1 Homo sapiens 58-63 22885662-7 2012 Altogether, our results identify the downstream elements (Egr-1, Nab-2, and MMP-2) by which halofuginone exerts its antitumoral effect, thereby advancing its potential therapeutic application as an anticancer drug. halofuginone 92-104 NGFI-A binding protein 2 Homo sapiens 65-70 22885662-7 2012 Altogether, our results identify the downstream elements (Egr-1, Nab-2, and MMP-2) by which halofuginone exerts its antitumoral effect, thereby advancing its potential therapeutic application as an anticancer drug. halofuginone 92-104 matrix metallopeptidase 2 Homo sapiens 76-81 22971531-5 2012 After injected with halofuginone, we observed a decrease in the number of CD4(+) interleukin (IL)-17(+) cells and a parallel increase in that of CD4(+) interferon (IFN)-gamma(+) cells in peripheral blood. halofuginone 20-32 CD4 antigen Mus musculus 146-149 22393274-0 2012 Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. halofuginone 0-12 SMAD family member 3 Homo sapiens 28-33 22393274-0 2012 Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 62-69 22393274-1 2012 PURPOSE: Due to its ability to disrupt transforming growth factor beta (TGF-beta) signaling, halofuginone has been successfully used to treat various fibrotic disorders. halofuginone 93-105 transforming growth factor beta 1 Homo sapiens 39-70 22393274-1 2012 PURPOSE: Due to its ability to disrupt transforming growth factor beta (TGF-beta) signaling, halofuginone has been successfully used to treat various fibrotic disorders. halofuginone 93-105 transforming growth factor beta 1 Homo sapiens 72-80 22393274-4 2012 TGF-beta was used to stimulate pro-fibrotic responses from corneal fibroblasts under halofuginone treatment. halofuginone 85-97 transforming growth factor beta 1 Homo sapiens 0-8 22393274-11 2012 Interestingly, under our experimental conditions, halofuginone treatment led to reduced protein expression of Smad3, which was both dose- and time-dependent. halofuginone 50-62 SMAD family member 3 Homo sapiens 110-115 21078281-3 2011 To address this need, we constructed an immune single-chain variable fragment (scFv) library from the RNA of a halofuginone-immunized chicken and selected halofuginone-specific scFv by phage display. halofuginone 111-123 immunglobulin heavy chain variable region Homo sapiens 79-83 22848627-4 2012 Inhibition of tumor invasion by stroma cells was achieved with halofuginone, an inhibitor of TGFbeta/Smad3 signaling, alone or in combination with chemotherapy. halofuginone 63-75 SMAD family member 3 Mus musculus 101-106 21078281-3 2011 To address this need, we constructed an immune single-chain variable fragment (scFv) library from the RNA of a halofuginone-immunized chicken and selected halofuginone-specific scFv by phage display. halofuginone 155-167 immunglobulin heavy chain variable region Homo sapiens 79-83 21078281-3 2011 To address this need, we constructed an immune single-chain variable fragment (scFv) library from the RNA of a halofuginone-immunized chicken and selected halofuginone-specific scFv by phage display. halofuginone 155-167 immunglobulin heavy chain variable region Homo sapiens 177-181 21078281-8 2011 This resulted in a heavy-chain-biased library from which an scFv with the potential to detect halofuginone residues as low as 80 pg/ml was isolated, a 185-fold improvement over the original scFv. halofuginone 94-106 immunglobulin heavy chain variable region Homo sapiens 60-64 21078281-8 2011 This resulted in a heavy-chain-biased library from which an scFv with the potential to detect halofuginone residues as low as 80 pg/ml was isolated, a 185-fold improvement over the original scFv. halofuginone 94-106 immunglobulin heavy chain variable region Homo sapiens 190-194 21078281-9 2011 This new chain-shuffled scFv was incorporated into a validated ELISA (according to Commission Regulation 2002/657/EC) for the sensitive detection of halofuginone in spiked processed egg samples. halofuginone 149-161 immunglobulin heavy chain variable region Homo sapiens 24-28 22053203-2 2011 Halofuginone (HF), a low-molecular-weight alkaloid that modulates TGFbeta signaling, was used to treat APL cell lines and non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice subjected to transplantation with leukemic cells from human chorionic gonadotrophin-PML-RARalpha transgenic mice (TG). halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 66-73 21117034-8 2011 Halofuginone, an inhibitor of Smad3 phosphorylation downstream of TGFbeta signaling, inhibits the activation of fibroblasts and their ability to synthesize ECM, regardless of their origin or location. halofuginone 0-12 SMAD family member 3 Homo sapiens 30-35 21117034-8 2011 Halofuginone, an inhibitor of Smad3 phosphorylation downstream of TGFbeta signaling, inhibits the activation of fibroblasts and their ability to synthesize ECM, regardless of their origin or location. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 66-73 21117034-10 2011 Recently, these halofuginone-dependent improvements were also observed in MD with minor fibrosis involvement, probably due to a direct effect of halofuginone on muscle cells, resulting in myotube fusion that is dependent on Akt and MAPK pathway activation. halofuginone 16-28 AKT serine/threonine kinase 1 Homo sapiens 224-227 21117034-10 2011 Recently, these halofuginone-dependent improvements were also observed in MD with minor fibrosis involvement, probably due to a direct effect of halofuginone on muscle cells, resulting in myotube fusion that is dependent on Akt and MAPK pathway activation. halofuginone 145-157 AKT serine/threonine kinase 1 Homo sapiens 224-227 21068672-1 2011 Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. halofuginone 115-127 matrix metallopeptidase 2 Homo sapiens 216-220 22053203-2 2011 Halofuginone (HF), a low-molecular-weight alkaloid that modulates TGFbeta signaling, was used to treat APL cell lines and non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice subjected to transplantation with leukemic cells from human chorionic gonadotrophin-PML-RARalpha transgenic mice (TG). halofuginone 0-12 PML nuclear body scaffold Homo sapiens 274-277 22053203-2 2011 Halofuginone (HF), a low-molecular-weight alkaloid that modulates TGFbeta signaling, was used to treat APL cell lines and non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice subjected to transplantation with leukemic cells from human chorionic gonadotrophin-PML-RARalpha transgenic mice (TG). halofuginone 0-12 retinoic acid receptor alpha Homo sapiens 278-286 20442678-11 2010 Preincubation of the PSCs with halofuginone elicited Cygb/STAP level reduction and tumor growth inhibition. halofuginone 31-43 cytoglobin Mus musculus 53-57 20944000-3 2010 For Th17 cells, IDO-mediated tryptophan deprivation and small molecule halofuginone-induced amino acid starvation response were shown to activate general control nonrepressed 2 (GCN2) kinase that directly or indirectly inhibits Th17 cell differentiation. halofuginone 71-83 indoleamine 2,3-dioxygenase 1 Mus musculus 16-19 20944000-3 2010 For Th17 cells, IDO-mediated tryptophan deprivation and small molecule halofuginone-induced amino acid starvation response were shown to activate general control nonrepressed 2 (GCN2) kinase that directly or indirectly inhibits Th17 cell differentiation. halofuginone 71-83 eukaryotic translation initiation factor 2 alpha kinase 4 Mus musculus 146-176 20944000-3 2010 For Th17 cells, IDO-mediated tryptophan deprivation and small molecule halofuginone-induced amino acid starvation response were shown to activate general control nonrepressed 2 (GCN2) kinase that directly or indirectly inhibits Th17 cell differentiation. halofuginone 71-83 eukaryotic translation initiation factor 2 alpha kinase 4 Mus musculus 178-182 20442678-11 2010 Preincubation of the PSCs with halofuginone elicited Cygb/STAP level reduction and tumor growth inhibition. halofuginone 31-43 polyamine modulated factor 1 binding protein 1 Mus musculus 58-62 20060825-0 2010 Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. halofuginone 0-12 SMAD family member 3 Mus musculus 22-27 20060825-0 2010 Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. halofuginone 0-12 thymoma viral proto-oncogene 1 Mus musculus 57-60 20060825-0 2010 Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. halofuginone 0-12 mitogen-activated protein kinase 1 Mus musculus 70-73 20060825-1 2010 Halofuginone, a novel inhibitor of Smad3 phosphorylation, has been shown to inhibit muscle fibrosis and to improve cardiac and skeletal muscle functions in the mdx mouse model of Duchenne muscular dystrophy. halofuginone 0-12 SMAD family member 3 Mus musculus 35-40 20060825-2 2010 Here, we demonstrate that halofuginone promotes the phosphorylation of Akt and mitogen-activated protein kinase (MAPK) family members in a C2 muscle cell line and in primary myoblasts derived from wild-type and mdx mice diaphragms. halofuginone 26-38 thymoma viral proto-oncogene 1 Mus musculus 71-74 20060825-3 2010 Halofuginone enhanced the association of phosphorylated Akt and MAPK/extracellular signal-regulated protein kinase (ERK) with the non-phosphorylated form of Smad3, accompanied by a reduction in Smad3 phosphorylation levels. halofuginone 0-12 thymoma viral proto-oncogene 1 Mus musculus 56-59 20060825-3 2010 Halofuginone enhanced the association of phosphorylated Akt and MAPK/extracellular signal-regulated protein kinase (ERK) with the non-phosphorylated form of Smad3, accompanied by a reduction in Smad3 phosphorylation levels. halofuginone 0-12 mitogen-activated protein kinase 1 Mus musculus 116-119 20060825-3 2010 Halofuginone enhanced the association of phosphorylated Akt and MAPK/extracellular signal-regulated protein kinase (ERK) with the non-phosphorylated form of Smad3, accompanied by a reduction in Smad3 phosphorylation levels. halofuginone 0-12 SMAD family member 3 Mus musculus 157-162 20060825-3 2010 Halofuginone enhanced the association of phosphorylated Akt and MAPK/extracellular signal-regulated protein kinase (ERK) with the non-phosphorylated form of Smad3, accompanied by a reduction in Smad3 phosphorylation levels. halofuginone 0-12 SMAD family member 3 Mus musculus 194-199 20060825-4 2010 This reduction was reversed by inhibitors of the phosphoinositide 3"-kinase/Akt (PI3K/Akt) and MAPK/ERK pathways, suggesting their specific role in mediating halofuginone"s inhibitory effect on Smad3 phosphorylation. halofuginone 158-170 thymoma viral proto-oncogene 1 Mus musculus 76-79 20060825-4 2010 This reduction was reversed by inhibitors of the phosphoinositide 3"-kinase/Akt (PI3K/Akt) and MAPK/ERK pathways, suggesting their specific role in mediating halofuginone"s inhibitory effect on Smad3 phosphorylation. halofuginone 158-170 phosphoinositide-3-kinase regulatory subunit 1 Mus musculus 81-89 20060825-4 2010 This reduction was reversed by inhibitors of the phosphoinositide 3"-kinase/Akt (PI3K/Akt) and MAPK/ERK pathways, suggesting their specific role in mediating halofuginone"s inhibitory effect on Smad3 phosphorylation. halofuginone 158-170 mitogen-activated protein kinase 1 Mus musculus 100-103 20060825-4 2010 This reduction was reversed by inhibitors of the phosphoinositide 3"-kinase/Akt (PI3K/Akt) and MAPK/ERK pathways, suggesting their specific role in mediating halofuginone"s inhibitory effect on Smad3 phosphorylation. halofuginone 158-170 SMAD family member 3 Mus musculus 194-199 20060825-5 2010 Halofuginone enhanced Akt, MAPK/ERK and p38 MAPK phosphorylation and inhibited Smad3 phosphorylation in myotubes, all of which are crucial for myotube fusion. halofuginone 0-12 thymoma viral proto-oncogene 1 Mus musculus 22-25 20060825-5 2010 Halofuginone enhanced Akt, MAPK/ERK and p38 MAPK phosphorylation and inhibited Smad3 phosphorylation in myotubes, all of which are crucial for myotube fusion. halofuginone 0-12 mitogen-activated protein kinase 1 Mus musculus 32-35 20060825-5 2010 Halofuginone enhanced Akt, MAPK/ERK and p38 MAPK phosphorylation and inhibited Smad3 phosphorylation in myotubes, all of which are crucial for myotube fusion. halofuginone 0-12 mitogen-activated protein kinase 14 Mus musculus 40-48 20060825-5 2010 Halofuginone enhanced Akt, MAPK/ERK and p38 MAPK phosphorylation and inhibited Smad3 phosphorylation in myotubes, all of which are crucial for myotube fusion. halofuginone 0-12 SMAD family member 3 Mus musculus 79-84 20060825-6 2010 In addition, halofuginone increased the association Akt and MAPK/ERK with Smad3. halofuginone 13-25 thymoma viral proto-oncogene 1 Mus musculus 52-55 20060825-6 2010 In addition, halofuginone increased the association Akt and MAPK/ERK with Smad3. halofuginone 13-25 mitogen-activated protein kinase 1 Mus musculus 65-68 20060825-6 2010 In addition, halofuginone increased the association Akt and MAPK/ERK with Smad3. halofuginone 13-25 SMAD family member 3 Mus musculus 74-79 20060825-7 2010 As a consequence, halofuginone promoted myotube fusion, as reflected by an increased percentage of C2 and mdx myotubes containing high numbers of nuclei, and this was reversed by specific inhibitors of the PI3K and MAPK/ERK pathways. halofuginone 18-30 mitogen-activated protein kinase 1 Mus musculus 220-223 20060825-8 2010 Together, the data suggest a role, either direct or via inhibition of Smad3 phosphorylation, for Akt or MAPK/ERK in halofuginone-enhanced myotube fusion, a feature which is crucial to improving muscle function in muscular dystrophies. halofuginone 116-128 SMAD family member 3 Mus musculus 70-75 20060825-8 2010 Together, the data suggest a role, either direct or via inhibition of Smad3 phosphorylation, for Akt or MAPK/ERK in halofuginone-enhanced myotube fusion, a feature which is crucial to improving muscle function in muscular dystrophies. halofuginone 116-128 thymoma viral proto-oncogene 1 Mus musculus 97-100 20060825-8 2010 Together, the data suggest a role, either direct or via inhibition of Smad3 phosphorylation, for Akt or MAPK/ERK in halofuginone-enhanced myotube fusion, a feature which is crucial to improving muscle function in muscular dystrophies. halofuginone 116-128 mitogen-activated protein kinase 1 Mus musculus 109-112 19713035-3 2010 The present study evaluated the effects of interfering with the TGF-beta signaling pathway on the radiosensitivity of selected human tumor cell lines using the plant-derived alkaloid, halofuginone. halofuginone 184-196 transforming growth factor beta 1 Homo sapiens 64-72 19713035-4 2010 Halofuginone treatment inhibited cell growth, halted cell cycle progression, decreased radiation-induced DNA damage repair, and decreased TGF-beta receptor II protein levels, leading to increased cellular radiosensitization. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 138-146 19578745-3 2009 Previous studies with halofuginone have shown it to inhibit TGF-beta signaling in vitro and protect mice from radiation-induced leg contraction (a model for soft tissue fibrosis). halofuginone 22-34 transforming growth factor, beta 1 Mus musculus 60-68 19135664-9 2010 Halofuginone also significantly reduced collagen type I (alpha1) and collagen type III (alpha1) mRNA levels, as well as the profibrotic factor TGFbeta1 mRNA levels in both cell types. halofuginone 0-12 collagen type III alpha 1 chain Homo sapiens 40-94 19578745-6 2009 Halofuginone treatment was shown to attenuate TGF-beta signaling molecules taken from irradiated skin including TGF-betaRII, pSmad3, Smad7, and TSP1. halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 46-54 19578745-6 2009 Halofuginone treatment was shown to attenuate TGF-beta signaling molecules taken from irradiated skin including TGF-betaRII, pSmad3, Smad7, and TSP1. halofuginone 0-12 SMAD family member 7 Mus musculus 133-138 19578745-6 2009 Halofuginone treatment was shown to attenuate TGF-beta signaling molecules taken from irradiated skin including TGF-betaRII, pSmad3, Smad7, and TSP1. halofuginone 0-12 tumor suppressor region 1 Mus musculus 144-148 19578745-7 2009 The latter, TSP1, a co-activator of TGF-beta may serve as a suitable biomarker for monitoring the efficacy of halofuginone should it be evaluated in a clinical setting for protection against radiation-induced fibrosis. halofuginone 110-122 tumor suppressor region 1 Mus musculus 12-16 19578745-7 2009 The latter, TSP1, a co-activator of TGF-beta may serve as a suitable biomarker for monitoring the efficacy of halofuginone should it be evaluated in a clinical setting for protection against radiation-induced fibrosis. halofuginone 110-122 transforming growth factor, beta 1 Mus musculus 36-44 18672370-7 2008 Halofuginone inhibited Smad3 phosphorylation downstream of TGFbeta in the diaphragm and cardiac muscles, in C2 cell line and in primary mouse myoblast cultures representing various muscular dystrophies. halofuginone 0-12 SMAD family member 3 Mus musculus 23-28 19188864-6 2009 RESULTS: Halofuginone prevented cerulein-dependent increase in collagen synthesis, collagen cross-linking enzyme P4Hbeta, Cygb/STAP, and tissue inhibitors of metalloproteinase 2. halofuginone 9-21 prolyl 4-hydroxylase, beta polypeptide Mus musculus 113-120 19188864-6 2009 RESULTS: Halofuginone prevented cerulein-dependent increase in collagen synthesis, collagen cross-linking enzyme P4Hbeta, Cygb/STAP, and tissue inhibitors of metalloproteinase 2. halofuginone 9-21 cytoglobin Mus musculus 122-126 19188864-6 2009 RESULTS: Halofuginone prevented cerulein-dependent increase in collagen synthesis, collagen cross-linking enzyme P4Hbeta, Cygb/STAP, and tissue inhibitors of metalloproteinase 2. halofuginone 9-21 sequestosome 1 Mus musculus 127-131 19188864-7 2009 Halofuginone did not affect TGFbeta levels in cerulein-treated mice but inhibited serum response factor synthesis and Smad3 phosphorylation. halofuginone 0-12 SMAD family member 3 Mus musculus 118-123 19188864-8 2009 In culture, halofuginone inhibited pancreatic stellate cell (PSC) proliferation and TGFbeta-dependent increase in Cygb/STAP and transgelin synthesis and metalloproteinase 2 activity. halofuginone 12-24 transforming growth factor, beta 1 Mus musculus 84-91 19188864-8 2009 In culture, halofuginone inhibited pancreatic stellate cell (PSC) proliferation and TGFbeta-dependent increase in Cygb/STAP and transgelin synthesis and metalloproteinase 2 activity. halofuginone 12-24 cytoglobin Mus musculus 114-118 19188864-8 2009 In culture, halofuginone inhibited pancreatic stellate cell (PSC) proliferation and TGFbeta-dependent increase in Cygb/STAP and transgelin synthesis and metalloproteinase 2 activity. halofuginone 12-24 sequestosome 1 Mus musculus 119-123 19188864-8 2009 In culture, halofuginone inhibited pancreatic stellate cell (PSC) proliferation and TGFbeta-dependent increase in Cygb/STAP and transgelin synthesis and metalloproteinase 2 activity. halofuginone 12-24 transgelin Mus musculus 128-138 19188864-10 2009 Halofuginone prevented the increase in acinar cell proliferation and further increased the cerulein-dependent PAP-1 synthesis. halofuginone 0-12 regenerating islet-derived 3 beta Mus musculus 110-115 19188864-11 2009 CONCLUSIONS: Halofuginone inhibits Smad3 phosphorylation and increases c-Jun N-terminal kinase phosphorylation, leading to the inhibition of PSC activation and consequent prevention of fibrosis. halofuginone 13-25 SMAD family member 3 Mus musculus 35-40 19188864-12 2009 Halofuginone increased the synthesis of PAP-1, which further reduces pancreas fibrosis. halofuginone 0-12 regenerating islet-derived 3 beta Mus musculus 40-45 19114027-2 2009 Halofuginone, an analog of febrifugine, has been shown to block TGF-beta(1) signaling and subsequent type I collagen production. halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 64-75 19114027-4 2009 Halofuginone suppressed Smad2 phosphorylation induced by TGF-beta(1) in cultured mesangial cells. halofuginone 0-12 SMAD family member 2 Mus musculus 24-29 19114027-4 2009 Halofuginone suppressed Smad2 phosphorylation induced by TGF-beta(1) in cultured mesangial cells. halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 57-68 19114027-6 2009 Halofuginone showed an inhibitory effect on type I collagen and fibronectin expression promoted by TGF-beta(1). halofuginone 0-12 fibronectin 1 Mus musculus 64-75 19114027-6 2009 Halofuginone showed an inhibitory effect on type I collagen and fibronectin expression promoted by TGF-beta(1). halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 99-110 19114027-7 2009 An in vivo experiment using db/db mice confirmed the ability of halofuginone to suppress mesangial expansion and fibronectin overexpression in the kidneys. halofuginone 64-76 fibronectin 1 Mus musculus 113-124 19793022-8 2009 Halofuginone treatment to animals with GEN-induced renal injury caused a significant decrease in serum blood urea nitrogen level and reduced the elevated MDA, GSH content, and MPO activity. halofuginone 0-12 myeloperoxidase Rattus norvegicus 176-179 18672370-7 2008 Halofuginone inhibited Smad3 phosphorylation downstream of TGFbeta in the diaphragm and cardiac muscles, in C2 cell line and in primary mouse myoblast cultures representing various muscular dystrophies. halofuginone 0-12 transforming growth factor, beta 1 Mus musculus 59-66 18672370-8 2008 We suggest that via its effect on Smad3 phosphorylation, halofuginone inhibits muscle fibrosis and improves cardiac and skeletal muscle functions in mdx mice. halofuginone 57-69 SMAD family member 3 Mus musculus 34-39 18458672-5 2008 We further demonstrated that treating fibrotic rat livers with halofuginone (HF), a multipotent antifibrogenic drug, and subsequently subjecting them to hydrodynamics-based transfection with human VEGF-165 resulted in elevated expression of heparanase mRNA. halofuginone 63-75 vascular endothelial growth factor A Rattus norvegicus 197-201 18714394-9 2008 Halofuginone, an inhibitor of myofibroblasts" activation and Smad3 phosphorylation, inhibited tumor development in xenografts derived from renal carcinoma cells harboring a reciprocal ASPL-TFE3 fusion transcript. halofuginone 0-12 SMAD family member 3 Homo sapiens 61-66 18714394-9 2008 Halofuginone, an inhibitor of myofibroblasts" activation and Smad3 phosphorylation, inhibited tumor development in xenografts derived from renal carcinoma cells harboring a reciprocal ASPL-TFE3 fusion transcript. halofuginone 0-12 ASPSCR1 tether for SLC2A4, UBX domain containing Homo sapiens 184-188 18714394-9 2008 Halofuginone, an inhibitor of myofibroblasts" activation and Smad3 phosphorylation, inhibited tumor development in xenografts derived from renal carcinoma cells harboring a reciprocal ASPL-TFE3 fusion transcript. halofuginone 0-12 transcription factor binding to IGHM enhancer 3 Homo sapiens 189-193 18458672-0 2008 Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats. halofuginone 0-12 heparanase Rattus norvegicus 43-53 18458672-5 2008 We further demonstrated that treating fibrotic rat livers with halofuginone (HF), a multipotent antifibrogenic drug, and subsequently subjecting them to hydrodynamics-based transfection with human VEGF-165 resulted in elevated expression of heparanase mRNA. halofuginone 63-75 heparanase Homo sapiens 241-251 23480137-3 2008 Halofuginone, an inhibitor of the Smad3 phosphorylation, downstream of the TGFbeta signaling, inhibits the activation of fibroblasts and their ability to synthesize the extracellular matrix, regardless of their origin or location. halofuginone 0-12 SMAD family member 3 Homo sapiens 34-39 16769768-3 2006 It was demonstrated recently that halofuginone inhibits transforming growth factor-beta (TGF-beta), an important immunomodulator. halofuginone 34-46 transforming growth factor beta 1 Homo sapiens 56-87 17180598-0 2007 Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. halofuginone 68-80 transforming growth factor beta 1 Homo sapiens 84-92 17180598-3 2007 Halofuginone, an inhibitor of liver fibrosis, inhibits TGF-beta-dependent Smad3 phosphorylation in human HSCs in culture. halofuginone 0-12 transforming growth factor beta 1 Homo sapiens 55-63 17180598-3 2007 Halofuginone, an inhibitor of liver fibrosis, inhibits TGF-beta-dependent Smad3 phosphorylation in human HSCs in culture. halofuginone 0-12 SMAD family member 3 Homo sapiens 74-79 17180598-8 2007 The activation of TGF-beta-dependent genes, such as tartrate-resistant acid phosphatase, its putative substrate osteopontin, stellate cell activation-association protein, and fibrillin-1, during chemically induced fibrosis is prevented by halofuginone. halofuginone 239-251 transforming growth factor beta 1 Homo sapiens 18-26 17180598-8 2007 The activation of TGF-beta-dependent genes, such as tartrate-resistant acid phosphatase, its putative substrate osteopontin, stellate cell activation-association protein, and fibrillin-1, during chemically induced fibrosis is prevented by halofuginone. halofuginone 239-251 secreted phosphoprotein 1 Homo sapiens 112-123 17180598-8 2007 The activation of TGF-beta-dependent genes, such as tartrate-resistant acid phosphatase, its putative substrate osteopontin, stellate cell activation-association protein, and fibrillin-1, during chemically induced fibrosis is prevented by halofuginone. halofuginone 239-251 fibrillin 1 Homo sapiens 175-186 17267660-6 2007 In prostate cancer and Wilms" tumor xenografts, halofuginone, but not the respective chemotherapies, inhibited the synthesis of collagen type I, alpha-smooth muscle actin, transgelin, and cytoglobin, all of which are characteristics of activated myofibroblasts. halofuginone 48-60 transgelin Homo sapiens 172-182 17267660-6 2007 In prostate cancer and Wilms" tumor xenografts, halofuginone, but not the respective chemotherapies, inhibited the synthesis of collagen type I, alpha-smooth muscle actin, transgelin, and cytoglobin, all of which are characteristics of activated myofibroblasts. halofuginone 48-60 cytoglobin Homo sapiens 188-198 17267660-7 2007 Halofuginone, as the respective chemotherapies, increased the synthesis of Wilms" tumor suppressor gene product (WT-1) and prostate apoptosis response gene-4 (Par-4), resulting in apoptosis/necrosis. halofuginone 0-12 pro-apoptotic WT1 regulator Homo sapiens 123-157 17267660-7 2007 Halofuginone, as the respective chemotherapies, increased the synthesis of Wilms" tumor suppressor gene product (WT-1) and prostate apoptosis response gene-4 (Par-4), resulting in apoptosis/necrosis. halofuginone 0-12 pro-apoptotic WT1 regulator Homo sapiens 159-164 16769768-3 2006 It was demonstrated recently that halofuginone inhibits transforming growth factor-beta (TGF-beta), an important immunomodulator. halofuginone 34-46 transforming growth factor beta 1 Homo sapiens 89-97 16769768-8 2006 In addition, 40 ng/ml halofuginone inhibited secretion of TNF-alpha, IFN-gamma, interleukin (IL)-4, IL-13, and TGF-beta (P < 0.005). halofuginone 22-34 tumor necrosis factor Homo sapiens 58-67 16769768-8 2006 In addition, 40 ng/ml halofuginone inhibited secretion of TNF-alpha, IFN-gamma, interleukin (IL)-4, IL-13, and TGF-beta (P < 0.005). halofuginone 22-34 interferon gamma Homo sapiens 69-78 16769768-8 2006 In addition, 40 ng/ml halofuginone inhibited secretion of TNF-alpha, IFN-gamma, interleukin (IL)-4, IL-13, and TGF-beta (P < 0.005). halofuginone 22-34 interleukin 13 Homo sapiens 100-105 16769768-8 2006 In addition, 40 ng/ml halofuginone inhibited secretion of TNF-alpha, IFN-gamma, interleukin (IL)-4, IL-13, and TGF-beta (P < 0.005). halofuginone 22-34 transforming growth factor beta 1 Homo sapiens 111-119 16508789-0 2006 Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone. halofuginone 144-156 protein tyrosine phosphatase 4A1 Homo sapiens 74-79 16489207-0 2006 Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. halofuginone 0-12 mitogen activated protein kinase 14 Rattus norvegicus 95-98 16489207-6 2006 HAL (200 nm) up-regulated matrix metalloproteinase (MMP)-3 and MMP-13 expression between 10- and 50-fold, resulting in a 2- to 3-fold increase of interstitial collagenase activity. halofuginone 0-3 matrix metallopeptidase 3 Rattus norvegicus 26-58 16489207-6 2006 HAL (200 nm) up-regulated matrix metalloproteinase (MMP)-3 and MMP-13 expression between 10- and 50-fold, resulting in a 2- to 3-fold increase of interstitial collagenase activity. halofuginone 0-3 matrix metallopeptidase 13 Rattus norvegicus 63-69 16489207-8 2006 p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor kappaB(NFkappaB) pathways were activated by HAL, and specific inhibitors of p38 MAPK and NFkappaB dose dependently inhibited MMP-13 induction. halofuginone 111-114 mitogen activated protein kinase 14 Rattus norvegicus 0-36 16489207-8 2006 p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor kappaB(NFkappaB) pathways were activated by HAL, and specific inhibitors of p38 MAPK and NFkappaB dose dependently inhibited MMP-13 induction. halofuginone 111-114 mitogen activated protein kinase 14 Rattus norvegicus 38-46 16489207-8 2006 p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor kappaB(NFkappaB) pathways were activated by HAL, and specific inhibitors of p38 MAPK and NFkappaB dose dependently inhibited MMP-13 induction. halofuginone 111-114 mitogen activated protein kinase 14 Rattus norvegicus 143-151 16489207-8 2006 p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor kappaB(NFkappaB) pathways were activated by HAL, and specific inhibitors of p38 MAPK and NFkappaB dose dependently inhibited MMP-13 induction. halofuginone 111-114 matrix metallopeptidase 13 Rattus norvegicus 192-198 16489207-10 2006 In vivo HAL up-regulated MMP-3 and -13 mRNA expression 1.5- and 2-fold, respectively, in cirrhotic rats, whereas tissue inhibitor of metalloproteinase-1 was suppressed by 50%. halofuginone 8-11 matrix metallopeptidase 3 Rattus norvegicus 25-38 16489207-11 2006 In conclusion, submicromolar concentrations of HAL inhibit HSC proliferation and migration and up-regulate their expression of fibrolytic MMP-3 and -13 via activation of p38 MAPK and NFkappaB. halofuginone 47-50 matrix metallopeptidase 3 Rattus norvegicus 138-151 16489207-11 2006 In conclusion, submicromolar concentrations of HAL inhibit HSC proliferation and migration and up-regulate their expression of fibrolytic MMP-3 and -13 via activation of p38 MAPK and NFkappaB. halofuginone 47-50 mitogen activated protein kinase 14 Rattus norvegicus 170-178 16489207-12 2006 The remarkable induction of MMP-3 and -13 makes HAL a promising agent for antifibrotic combination therapies. halofuginone 48-51 matrix metallopeptidase 3 Rattus norvegicus 28-41 16508789-8 2006 In addition, halofuginone augmented PRL-1 expression in the remnant liver after partial hepatectomy and in chemically induced fibrosis in rats; this was accompanied by increased expression of insulin-like growth factor binding protein 1 (IGFBP-1), another immediate-early gene of regeneration. halofuginone 13-25 insulin-like growth factor binding protein 1 Rattus norvegicus 238-245 16508789-9 2006 The regulation of the expression of the early genes of regeneration such as PRL-1 and IGFBP-1 is thus part of the mode of action of halofuginone and results in the prevention of liver fibrosis and improved cirrhotic liver regeneration. halofuginone 132-144 protein tyrosine phosphatase 4A1 Homo sapiens 76-81 16508789-9 2006 The regulation of the expression of the early genes of regeneration such as PRL-1 and IGFBP-1 is thus part of the mode of action of halofuginone and results in the prevention of liver fibrosis and improved cirrhotic liver regeneration. halofuginone 132-144 insulin like growth factor binding protein 1 Homo sapiens 86-93 16508789-3 2006 In this study, we evaluated the effect of halofuginone on PRL-1 expression, its cellular localization in vitro and during liver regeneration, and fibrosis progression in vivo. halofuginone 42-54 protein tyrosine phosphatase 4A1 Homo sapiens 58-63 16508789-4 2006 In culture, halofuginone increased PRL-1 expression in primary rat hepatocytes and in hepatocellular carcinoma (HCC) cell lines, the former being more sensitive to halofuginone. halofuginone 12-24 protein tyrosine phosphatase 4A1 Rattus norvegicus 35-40 16508789-5 2006 The halofuginone-dependent increase in PRL-1 gene expression was correlated with an increase in the transcription factor early growth response-1 (Egr-1) and inversely correlated with the inhibition of cell proliferation. halofuginone 4-16 protein tyrosine phosphatase 4A1 Homo sapiens 39-44 16508789-5 2006 The halofuginone-dependent increase in PRL-1 gene expression was correlated with an increase in the transcription factor early growth response-1 (Egr-1) and inversely correlated with the inhibition of cell proliferation. halofuginone 4-16 early growth response 1 Homo sapiens 146-151 16508789-7 2006 Halofuginone also affected the PRL-1 sub-cellular localization that was cell-cycle-dependent. halofuginone 0-12 protein tyrosine phosphatase 4A1 Homo sapiens 31-36 16508789-8 2006 In addition, halofuginone augmented PRL-1 expression in the remnant liver after partial hepatectomy and in chemically induced fibrosis in rats; this was accompanied by increased expression of insulin-like growth factor binding protein 1 (IGFBP-1), another immediate-early gene of regeneration. halofuginone 13-25 protein tyrosine phosphatase 4A1 Rattus norvegicus 36-41 16508789-8 2006 In addition, halofuginone augmented PRL-1 expression in the remnant liver after partial hepatectomy and in chemically induced fibrosis in rats; this was accompanied by increased expression of insulin-like growth factor binding protein 1 (IGFBP-1), another immediate-early gene of regeneration. halofuginone 13-25 insulin-like growth factor binding protein 1 Rattus norvegicus 192-236 16735800-2 2006 Halofuginone is a nontoxic alkaloid, used as a coccidiostat, and is a potent inhibitor of collagen alpha(1)(I) and matrix metalloproteinase-2 (MMP-2) expression. halofuginone 0-12 matrix metallopeptidase 2 Rattus norvegicus 115-141 16756723-6 2006 MMP-9 activity was decreased in the halofuginone group by 89% and 63% in non-neoplastic parts of the liver and tumor, respectively. halofuginone 36-48 matrix metallopeptidase 9 Rattus norvegicus 0-5 16418571-0 2006 Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. halofuginone 0-12 thrombospondin 1 Mus musculus 79-95 16418571-2 2006 In vitro data suggested that halofuginone inhibits angiogenesis through upregulating thrombospondin-1 (TSP-1) expression and by inhibiting cell proliferation. halofuginone 29-41 thrombospondin 1 Mus musculus 85-101 16418571-2 2006 In vitro data suggested that halofuginone inhibits angiogenesis through upregulating thrombospondin-1 (TSP-1) expression and by inhibiting cell proliferation. halofuginone 29-41 thrombospondin 1 Mus musculus 103-108 16418571-6 2006 Interestingly, type I collagen level was lower in the halofuginone treated TSP-1+/+PyT tumors at 30 days, but this was not observed in the TSP-1-/-PyT mice. halofuginone 54-66 thrombospondin 1 Mus musculus 75-80 16418571-7 2006 Levels of type I collagen did not correlate with blood vessel number as a decrease in the number of vessels was observed in the halofuginone treated tumors from both the TSP-1+/+PyT and TSP-1-/-PyT mice as compared to control tumors. halofuginone 128-140 thrombospondin 1 Mus musculus 170-175 16418571-7 2006 Levels of type I collagen did not correlate with blood vessel number as a decrease in the number of vessels was observed in the halofuginone treated tumors from both the TSP-1+/+PyT and TSP-1-/-PyT mice as compared to control tumors. halofuginone 128-140 thrombospondin 1 Mus musculus 186-191 16418571-8 2006 Because halofuginone has been shown to inhibit type I collagen synthesis by inhibiting the TGF-beta signaling pathway, we measured Smad 2/3 phosphorylation levels and found that halofuginone inhibited Smad 2/3 phosphorylation in cells derived from TSP-1+/+PyT tumors. halofuginone 8-20 SMAD family member 2 Mus musculus 201-209 16418571-8 2006 Because halofuginone has been shown to inhibit type I collagen synthesis by inhibiting the TGF-beta signaling pathway, we measured Smad 2/3 phosphorylation levels and found that halofuginone inhibited Smad 2/3 phosphorylation in cells derived from TSP-1+/+PyT tumors. halofuginone 178-190 SMAD family member 2 Mus musculus 131-139 16418571-8 2006 Because halofuginone has been shown to inhibit type I collagen synthesis by inhibiting the TGF-beta signaling pathway, we measured Smad 2/3 phosphorylation levels and found that halofuginone inhibited Smad 2/3 phosphorylation in cells derived from TSP-1+/+PyT tumors. halofuginone 178-190 SMAD family member 2 Mus musculus 201-209 16418571-8 2006 Because halofuginone has been shown to inhibit type I collagen synthesis by inhibiting the TGF-beta signaling pathway, we measured Smad 2/3 phosphorylation levels and found that halofuginone inhibited Smad 2/3 phosphorylation in cells derived from TSP-1+/+PyT tumors. halofuginone 178-190 thrombospondin 1 Mus musculus 248-253 16418571-10 2006 Our data demonstrate that halofuginone inhibits mammary tumor growth in a transgenic mouse model via a TSP-1 independent pathway, by decreasing tumor angiogenesis and by inhibiting TGF-beta signaling. halofuginone 26-38 thrombospondin 1 Mus musculus 103-108 16735800-2 2006 Halofuginone is a nontoxic alkaloid, used as a coccidiostat, and is a potent inhibitor of collagen alpha(1)(I) and matrix metalloproteinase-2 (MMP-2) expression. halofuginone 0-12 matrix metallopeptidase 2 Rattus norvegicus 143-148 16735800-13 2006 Halofuginone at a concentration of 250 ng/ml almost completely abolished the effect of platelet-derived growth factor. halofuginone 0-12 myotrophin Rattus norvegicus 104-117 16735800-15 2006 CONCLUSIONS: Halofuginone exhibits antifibrotic effects in rat renal papillary fibroblasts in culture, in terms of inhibition of proliferation and inhibition of MMP-2. halofuginone 13-25 matrix metallopeptidase 2 Rattus norvegicus 161-166 15154911-9 2004 Additionally, inhibition of Smad3 by overexpression of the inhibitory Smad7 protein or by treatment with the small molecule, halofuginone, dramatically reduces responses in animal models of kidney, lung, liver and radiation-induced fibrosis. halofuginone 125-137 SMAD family member 3 Mus musculus 28-33 14732719-4 2004 In the current study, a small molecular weight molecule, halofuginone (100 nm), is demonstrated by reporter assays to inhibit the TGF-beta signaling pathway, by Northern blotting to elevate inhibitory Smad7 expression within 15 min, and by Western blotting to inhibit formation of phospho-Smad2 and phospho-Smad3 and to decrease cytosolic and membrane TGF-beta type II receptor (TbetaRII). halofuginone 57-69 transforming growth factor, beta 1 Mus musculus 130-138 14732719-4 2004 In the current study, a small molecular weight molecule, halofuginone (100 nm), is demonstrated by reporter assays to inhibit the TGF-beta signaling pathway, by Northern blotting to elevate inhibitory Smad7 expression within 15 min, and by Western blotting to inhibit formation of phospho-Smad2 and phospho-Smad3 and to decrease cytosolic and membrane TGF-beta type II receptor (TbetaRII). halofuginone 57-69 SMAD family member 7 Mus musculus 201-206 14732719-4 2004 In the current study, a small molecular weight molecule, halofuginone (100 nm), is demonstrated by reporter assays to inhibit the TGF-beta signaling pathway, by Northern blotting to elevate inhibitory Smad7 expression within 15 min, and by Western blotting to inhibit formation of phospho-Smad2 and phospho-Smad3 and to decrease cytosolic and membrane TGF-beta type II receptor (TbetaRII). halofuginone 57-69 SMAD family member 3 Mus musculus 307-312 14732719-4 2004 In the current study, a small molecular weight molecule, halofuginone (100 nm), is demonstrated by reporter assays to inhibit the TGF-beta signaling pathway, by Northern blotting to elevate inhibitory Smad7 expression within 15 min, and by Western blotting to inhibit formation of phospho-Smad2 and phospho-Smad3 and to decrease cytosolic and membrane TGF-beta type II receptor (TbetaRII). halofuginone 57-69 transforming growth factor, beta receptor II Mus musculus 352-377 14732719-4 2004 In the current study, a small molecular weight molecule, halofuginone (100 nm), is demonstrated by reporter assays to inhibit the TGF-beta signaling pathway, by Northern blotting to elevate inhibitory Smad7 expression within 15 min, and by Western blotting to inhibit formation of phospho-Smad2 and phospho-Smad3 and to decrease cytosolic and membrane TGF-beta type II receptor (TbetaRII). halofuginone 57-69 transforming growth factor, beta receptor II Mus musculus 379-387 14732719-5 2004 Attenuation of TbetaRII levels was noted as early as 1 h and down-regulation persisted for 24 h. Halofuginone blocked TGF-beta-induced delocalization of tight junction ZO-1, a marker of epidermal mesenchymal transition, in NMuMg mammary epithelial cells and suggest halofuginone may have in vivo anti-fibrogenesis characteristics. halofuginone 97-109 transforming growth factor, beta receptor II Mus musculus 15-23 14732719-5 2004 Attenuation of TbetaRII levels was noted as early as 1 h and down-regulation persisted for 24 h. Halofuginone blocked TGF-beta-induced delocalization of tight junction ZO-1, a marker of epidermal mesenchymal transition, in NMuMg mammary epithelial cells and suggest halofuginone may have in vivo anti-fibrogenesis characteristics. halofuginone 97-109 transforming growth factor, beta 1 Mus musculus 118-126 14732719-5 2004 Attenuation of TbetaRII levels was noted as early as 1 h and down-regulation persisted for 24 h. Halofuginone blocked TGF-beta-induced delocalization of tight junction ZO-1, a marker of epidermal mesenchymal transition, in NMuMg mammary epithelial cells and suggest halofuginone may have in vivo anti-fibrogenesis characteristics. halofuginone 266-278 transforming growth factor, beta receptor II Mus musculus 15-23 14732719-5 2004 Attenuation of TbetaRII levels was noted as early as 1 h and down-regulation persisted for 24 h. Halofuginone blocked TGF-beta-induced delocalization of tight junction ZO-1, a marker of epidermal mesenchymal transition, in NMuMg mammary epithelial cells and suggest halofuginone may have in vivo anti-fibrogenesis characteristics. halofuginone 266-278 transforming growth factor, beta 1 Mus musculus 118-126 14732719-9 2004 The results detail the molecular effects of halofuginone on the TGF-beta signal pathway and show that halofuginone may lessen radiation-induced fibrosis in humans. halofuginone 44-56 transforming growth factor beta 1 Homo sapiens 64-72 16148645-0 2005 Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. halofuginone 51-63 WT1 transcription factor Homo sapiens 96-100 16148645-9 2005 In culture halofuginone increased the synthesis of WT1 in the human WT cell-line SK-NEP-1 and in other cancer cell lines such as hepatocellular carcinoma and prostate cancer. halofuginone 11-23 WT1 transcription factor Homo sapiens 51-54 16148645-9 2005 In culture halofuginone increased the synthesis of WT1 in the human WT cell-line SK-NEP-1 and in other cancer cell lines such as hepatocellular carcinoma and prostate cancer. halofuginone 11-23 EMG1 N1-specific pseudouridine methyltransferase Homo sapiens 84-89 16148645-10 2005 In SK-NEP-1 halofuginone also lowered erb B2 levels and reduced cell proliferation. halofuginone 12-24 EMG1 N1-specific pseudouridine methyltransferase Homo sapiens 6-11 15177499-1 2004 Halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha 1 (I) and matrix metalloproteinase 2 gene expression. halofuginone 0-12 matrix metallopeptidase 2 Mus musculus 101-127 15177499-8 2004 The mechanism of the anti-tumour effect of halofuginone was determined in vitro by assessing tumour cell growth, and by measuring the serum concentrations of interferon-gamma (IFN gamma) and interleukin 2 (IL2). halofuginone 43-55 interferon gamma Mus musculus 158-174 15177499-8 2004 The mechanism of the anti-tumour effect of halofuginone was determined in vitro by assessing tumour cell growth, and by measuring the serum concentrations of interferon-gamma (IFN gamma) and interleukin 2 (IL2). halofuginone 43-55 interferon gamma Mus musculus 176-185 15177499-8 2004 The mechanism of the anti-tumour effect of halofuginone was determined in vitro by assessing tumour cell growth, and by measuring the serum concentrations of interferon-gamma (IFN gamma) and interleukin 2 (IL2). halofuginone 43-55 interleukin 2 Mus musculus 191-204 15177499-8 2004 The mechanism of the anti-tumour effect of halofuginone was determined in vitro by assessing tumour cell growth, and by measuring the serum concentrations of interferon-gamma (IFN gamma) and interleukin 2 (IL2). halofuginone 43-55 interleukin 2 Mus musculus 206-209 12869955-8 2003 Inhibition of collagen synthesis by halofuginone is achieved by inhibiting transforming growth factor beta-dependent Smad3 phosphorylation. halofuginone 36-48 transforming growth factor beta 1 Homo sapiens 75-106 14506172-12 2003 Immunohistochemical studies revealed decreased collagen type I levels and vascular density in treated tumors and gelatinase assays of tumor extracts revealed a reduction of MMP-2 and MMP-9 activity in halofuginone-treated cells. halofuginone 201-213 matrix metallopeptidase 2 Homo sapiens 173-178 14506172-12 2003 Immunohistochemical studies revealed decreased collagen type I levels and vascular density in treated tumors and gelatinase assays of tumor extracts revealed a reduction of MMP-2 and MMP-9 activity in halofuginone-treated cells. halofuginone 201-213 matrix metallopeptidase 9 Homo sapiens 183-188 12869955-8 2003 Inhibition of collagen synthesis by halofuginone is achieved by inhibiting transforming growth factor beta-dependent Smad3 phosphorylation. halofuginone 36-48 SMAD family member 3 Homo sapiens 117-122 12482197-6 2002 Our results demonstrate that halofuginone prevented the occurrence of skin sclerosis when administered to newborn mice and reduced cutaneous hyperplasia when administered in adult TSK mice. halofuginone 29-41 fibrillin 1 Mus musculus 180-183 12384935-13 2002 CONCLUSION: Our findings illustrate the powerful down-regulatory property of c-Jun toward type I collagen and establish that halofuginone exerts its effect on collagen synthesis in a c-Jun-dependent manner. halofuginone 125-137 jun proto-oncogene Mus musculus 183-188 12384935-0 2002 Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. halofuginone 0-12 collagen, type I, alpha 2 Mus musculus 27-33 12384935-0 2002 Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. halofuginone 0-12 jun proto-oncogene Mus musculus 58-63 12384935-3 2002 The present study further analyzed the ability of halofuginone to affect transcription factors that can regulate type I collagen gene expression by examining its effect on c-Jun, the negative regulator of collagen gene transcription. halofuginone 50-62 jun proto-oncogene Mus musculus 172-177 12384935-4 2002 METHODS: The phosphorylation state of c-Jun in the presence of halofuginone was examined via direct Western blotting, and the transcriptional activity of the activator protein 1 (AP-1) binding element via electrophoretic mobility shift assay and luciferase reporter assay. halofuginone 63-75 jun proto-oncogene Mus musculus 38-43 12384935-7 2002 We also determined whether halofuginone had an effect on the phosphorylation state of c-Jun in the skin of TSK/+ mice via immunohistochemistry. halofuginone 27-39 jun proto-oncogene Mus musculus 86-91 12384935-7 2002 We also determined whether halofuginone had an effect on the phosphorylation state of c-Jun in the skin of TSK/+ mice via immunohistochemistry. halofuginone 27-39 tsukushi, small leucine rich proteoglycan Mus musculus 107-110 12384935-8 2002 RESULTS: Treatment of fibroblasts with 10(-8)M halofuginone enhanced basal and mitogen-mediated phosphorylation of c-Jun in culture. halofuginone 47-59 jun proto-oncogene Mus musculus 115-120 12384935-10 2002 Overexpression of c-Jun enhanced in a dose-dependent manner the ability of halofuginone to inhibit the activity of a luciferase reporter construct under control of the -3200-bp to +54-bp COL1A2 promoter, whereas the expression of a dominant-negative c-Jun construct abolished this effect. halofuginone 75-87 jun proto-oncogene Mus musculus 18-23 12384935-10 2002 Overexpression of c-Jun enhanced in a dose-dependent manner the ability of halofuginone to inhibit the activity of a luciferase reporter construct under control of the -3200-bp to +54-bp COL1A2 promoter, whereas the expression of a dominant-negative c-Jun construct abolished this effect. halofuginone 75-87 collagen, type I, alpha 2 Mus musculus 187-193 12384935-10 2002 Overexpression of c-Jun enhanced in a dose-dependent manner the ability of halofuginone to inhibit the activity of a luciferase reporter construct under control of the -3200-bp to +54-bp COL1A2 promoter, whereas the expression of a dominant-negative c-Jun construct abolished this effect. halofuginone 75-87 jun proto-oncogene Mus musculus 250-255 12384935-11 2002 Northern blotting showed that overexpression of c-Jun enhanced the ability of halofuginone to reduce collagen alpha2(I) messenger RNA levels in fibroblasts, whereas expression of the dominant-negative c-Jun abolished this effect. halofuginone 78-90 jun proto-oncogene Mus musculus 48-53 12384935-12 2002 Topical administration of a halofuginone-containing cream for 20 days to TSK mice, which spontaneously develop dermal fibrosis, greatly increased the phosphorylated form of c-Jun in the skin; this was followed by a decrease in skin thickness and type I collagen messenger RNA expression. halofuginone 28-40 tsukushi, small leucine rich proteoglycan Mus musculus 73-76 12384935-12 2002 Topical administration of a halofuginone-containing cream for 20 days to TSK mice, which spontaneously develop dermal fibrosis, greatly increased the phosphorylated form of c-Jun in the skin; this was followed by a decrease in skin thickness and type I collagen messenger RNA expression. halofuginone 28-40 jun proto-oncogene Mus musculus 173-178 12384935-13 2002 CONCLUSION: Our findings illustrate the powerful down-regulatory property of c-Jun toward type I collagen and establish that halofuginone exerts its effect on collagen synthesis in a c-Jun-dependent manner. halofuginone 125-137 jun proto-oncogene Mus musculus 77-82 11874485-0 2002 Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. halofuginone 0-12 SMAD family member 3 Mus musculus 124-129 11874485-10 2002 Our results demonstrate that halofuginone is a specific inhibitor of type-I collagen synthesis and may elicit its effect via interference with the transforming growth factor beta signaling pathway. halofuginone 29-41 complement factor B Mus musculus 167-178 11874485-7 2002 In addition, analysis of transforming growth factor beta signaling pathways in fibroblasts revealed that halofuginone inhibited transforming-growth-factor-beta-induced upregulation of collagen protein and activity of the alpha2(I) collagen promoter. halofuginone 105-117 complement factor B Mus musculus 45-56 11874485-8 2002 Further we found that halofuginone blocked the phosphorylation and subsequent activation of Smad3 after transforming growth factor beta stimulation. halofuginone 22-34 SMAD family member 3 Mus musculus 92-97 11874485-8 2002 Further we found that halofuginone blocked the phosphorylation and subsequent activation of Smad3 after transforming growth factor beta stimulation. halofuginone 22-34 complement factor B Mus musculus 124-135 11705455-0 2001 Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. halofuginone 86-98 fibrillin 1 Mus musculus 36-46 11705455-0 2001 Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. halofuginone 86-98 fibrillin 1 Mus musculus 48-51 11705455-2 2001 Halofuginone-containing cream was applied on the tight-skin mouse (Tsk) and skin biopsies were taken for collagen staining by sirius red and for collagen alpha1(I) gene expression by in situ hybridization. halofuginone 0-12 fibrillin 1 Mus musculus 49-65 11705455-2 2001 Halofuginone-containing cream was applied on the tight-skin mouse (Tsk) and skin biopsies were taken for collagen staining by sirius red and for collagen alpha1(I) gene expression by in situ hybridization. halofuginone 0-12 fibrillin 1 Mus musculus 67-70